

Curriculum Vitae and Bibliography

Shaji K. Kumar, MD

Personal Information

Work Address: Mayo Clinic
200 First Street SW
Rochester, MN 55905
507-284-2017

Email Address: kumar.shaji@mayo.edu

Home Address: 1801 Scenic Point Ln SW
Rochester, MN 55902
507-529-0849

Present Academic Rank and Position

Consultant - Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 01/2008 - Present

Professor of Medicine - Mayo Clinic College of Medicine 09/2012 - Present

Education

Union Christian College - Pre-Medical 1985 - 1987

All-India Institute of Medical Sciences - MB BS 1987 - 1991

All-India Institute of Medical Sciences - Internship, Rotatory Internship 1992

All-India Institute of Medical Sciences - Clinical Residency, Internal Medicine 1993 - 1996

Institute Rotary Cancer Hospital, All-India Institute of Medical Sciences - Senior Resident, Medical Oncology 1996 - 1997

Mayo Graduate School of Medicine, Mayo Clinic College of Medicine - Clinical Residency, Internal Medicine 1997 - 1999

Mayo Graduate School of Medicine, Mayo Clinic College of Medicine - Fellow, Hematology/ Oncology 1999 - 2003

DFCI/Harvard Cancer Center - Research Associate, Mayo Foundation Scholar(Multiple Myeloma) 2003 - 2004

Additional Education

Certificate in Clinical and Translational Research
Mayo Clinic CTSA and Mayo Graduate School 08/2009

Clinical Epidemiology Workshop
Cancer Education Consortium
Brewster, Massachusetts 08/2002

Workshop in "Methods in Clinical Cancer Research"
American Association for Cancer Research
Vail, Colorado 07/2002

Workshop in "Molecular Biology in Clinical Oncology"
American Association for Cancer Research 06/2001

Completed Six weeks Training in Molecular Biology Techniques
Department of Biochemistry and Molecular Biology, Mayo Clinic 01/2001 - 02/2001

Certifications

Board Certifications

American Board of Internal Medicine (ABIM)

Medical Oncology	2004 - Present
Hematology	2004 - Present
Internal Medicine	1999 - Present

Educational Commission for Foreign Medical Graduates (ECFMG)

ECFMG	1996 - Present
-------	----------------

Medical Council of India

Internal Medicine	1993 - Present
-------------------	----------------

Licensure

India	11051 (Medical)
Minnesota	41493 (Medical)

Honors/Awards

Kirpal Kaur Award for Best Resident - Department of Medicine, All India Institute of Medical Sciences, New Delhi	01/1993
American Association of Cancer Research Award - Molecular Biology Workshop, Aspen, CO	07/2001
Travel Award for Presentation at Special Topic Conference on Hepatic Veno-occlusive Disease, Atlanta, GA - American Association for the Study of Liver Diseases	03/2002
Methods in Clinical Cancer Research Award - American Association for Cancer Research and American Society of Clinical Oncology Workshop	07/2002
Cancer Education Consortium Award - Epidemiology and Trial Design, Brewster, MA	08/2002
William Summerskill Award - Department of Internal Medicine, Mayo Clinic	01/2003
Merit Award - American Society of Clinical Oncology	01/2003

Previous Professional Positions and Major Appointments

Assistant Professor of Medicine - Mayo Clinic College of Medicine	04/2002 - 10/2006
Assistant Professor of Oncology - Mayo Clinic College of Medicine	04/2002 - 11/2007
Mayo Foundation Scholar - Dana-Farber Harvard Cancer Institute, Boston, Massachusetts	2003 - 2004
Senior Associate Consultant - Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota	2005 - 12/2007
Associate Professor of Medicine - Mayo Clinic College of Medicine	11/2006 - 08/2012

Professional & Community Memberships, Societies and Services**Professional Memberships & Services**

American Medical Association	
Member	01/1998 - Present
American Society for Blood and Marrow Transplantation	
Member	01/1999 - Present
American Society of Hematology	
Member	01/1999 - Present
American Society of Clinical Oncology	
Member	01/1999 - Present

American Association for Cancer Research Member	01/2000 - Present
European Hematology Association Member	07/2008 - Present
Society for Clinical Trials Active Member	04/2011

Journal Responsibilities

Journal Editorial Responsibilities

Advances in Hematology Board Member	
American Journal of Hematology Editorial Advisory Board	01/2009 - 12/2011
Associate Editor	12/2011 - Present
Leukemia Board Member	09/2010 - Present
European Journal of Clinical and Medical Oncology Board Member	07/2011 - Present

Journal Other Responsibilities

Advances in Therapy Advisory Board Member	06/2009 - Present
Clinical Oncology News Advisory Board Member	04/2011 - Present

Educational Activities

Curriculum/Course Development

BMT Core Curriculum
For Heme Onc Trainees
Graduate School of Medicine

Teaching Intramural

Multiple Myeloma: Current Approaches to Risk Adapted Therapy Professional Development Seminar for Nursing Staff Nursing	09/2011
Multiple Myeloma: mSMART approach Professional Development Seminar for Nursing Staff Nursing	03/2011
Myeloma: Clinical Manifestations, Prognostic Factors, and Treatment Mayo Graduate School of Medicine	03/2011
Current Approaches to Managing Multiple Myeloma Current Issues in Cancer Care Nursing	07/2009
Cord Blood Transplantation-Current Status BMT Core Curriculum Transplant Center, Mayo Clinic	01/2006
Multiple Myeloma – A Review Tuesday morning lecture series. Austin Medical Center Austin, Minnesota	06/2003

Effect of bcl2 Overexpression on Measles Virus Mediated Cytotoxicity in Lymphoma Cell Lines Molecular Medicine Program Presentation, Mayo Clinic Rochester, Minnesota	12/2002
Hepatic Venous-occlusive Disease (Sinusoidal Obstruction Syndrome) Post-hematopoietic Stem Cell Transplantation Hematology Core Curriculum Presentation Mayo Graduate School of Medicine	11/2002
Hepatic Venous-occlusive Disease Post Hematopoietic Stem Cell Transplantation Transplant Center Grand Rounds, Mayo Clinic Rochester, Minnesota	02/2002
Teaching Medical Students rotating through Hematology and Oncology in-patient teaching and consults services Mayo Medical School Rochester, Minnesota	
Teaching Medical Students rotating through Internal Medicine and sub-specialties in-patient services Mayo Medical School Rochester, Minnesota	
Mentorship	
Gonsalves, Wison (Hematology/Oncology Fellow)	07/2011 - Present
Rana, Vishal (Hematology/Oncology Fellow)	07/2011 - Present
Srivastava, Geetika (Hematology/Oncology Fellow) Current Status: Heme Onc Fellow at Mayo	07/2010 - Present
Madan, Sumit (Clinical Fellow) Current Status: Hematology Oncology Fellow, UT San Antonio Outcomes: Published several manuscripts related to myeloma, likely to pursue an academic career in hematological malignancies.	07/2009 - 06/2011
Ramakrishnan, Vijay (Basic Scientist Postdoctoral Fellow) Current Status: Post Doctoral Fellow	06/2009 - Present
Sinha, Shirshendu (Clinical Research Trainee) Current Status: Resident in psychiatry, University of Connecticut, CT Outcomes: Several publications related to myeloma. Long term goal of pursuing psychiatric aspects of oncology	01/2009 - 06/2011
Kapoor, Prashant (Research Fellow) Current Status: Fellow in Hematology Oncology at Mayo Outcomes: Several high impact papers in top journals on various aspects of myeloma, future staff position at Mayo.	01/2008 - Present
Naina, Harris V (Hematology/Oncology Fellow) Current Status: Faculty Member, Department of Hematology/Oncology, UT Southwestern, TX Outcomes: Publications, presentations related to transplantation.	07/2007 - 06/2010
Tan, Tow (Hematology/Oncology Fellow) Current Status: Private Practice	06/2007 - 06/2009
Zirkzadeh, Ali (Clinical Fellow) Current Status: Consultant, General Internal Medicine	09/2005 - 06/2009
Simpson, Lijo (Hematology/Oncology Fellow) Current Status: Private Practice	06/2005 - 06/2009

Academic Career Development

Faculty Enhancement and Educational Development Program
Mayo

12/2010

Institutional/Departmental Administrative Responsibilities, Committee Memberships and Other Activities

Mayo Clinic

Mayo Clinic Committees

Institutional Review Board

Member

01/2009 - Present

Mayo Clinic in Rochester

Department of Internal Medicine

Division of Hematology

Amyloid Interest Group

Member

Bone Marrow Transplant Program

Member

Hematology Education Committee

Member

Dysproteinemia Clinic

Member

Mayo Clinic Rochester Committees

Clinical Practice Committee - Rochester

Transfusion Subcommittee

Member

08/2008 - Present

Presentations Extramural

National/International

Invited

Emerging Treatment Options for Patients With Multiple Myeloma
Fifth Annual Review of the ASH Annual Meeting: Updates in the Treatment and
Management of Hematologic Malignancies
Nashville, Tennessee 01/2012

When and why do I use maintenance therapy in myeloma?
Indian Society of Hematology
Chandigarh, India 11/2011

How I treat relapsed and / or refractory Multiple Myeloma?
Indian Society of Hematology
Chandigarh, India 11/2011

Management of Multiple Myeloma: Impact of Novel Molecules
Targeted Therapy in Malignancy: Where the Future Is
New Delhi 11/2011

Stem Cell Transplantation for Myeloma: 2011 and Beyond
Hematologic Malignancies: New Therapies and the Evolving Role of Transplant
Chicago, Illinois 10/2011

Treatment of Newly Diagnosed Myeloma: Mayo Clinic Approach
Invited Lecture: University Hospital Department of Hematology
Krakow, Poland 10/2011

ASH 2010 Highlights: Multiple Myeloma ASH New York, New York	02/2011
Best of ASCO 2010: Treatment Approaches to Multiple Myeloma San Francisco, California	07/2010
Clinical Debates in Multiple Myeloma: The Evolving Role of Transplant City of Hope Duarte, California	01/2010
Multiple Myeloma: A "Decade of Progress" Medical Grand Rounds at University of Pittsburgh Pittsburgh, Pennsylvania	11/2009
Current Approaches to Managing Multiple Myeloma Oncology Nursing Society Tampa, Florida	10/2009
Stem cell transplantation in the era of novel agents: keeping options open EBMT Annual Meeting Education Program Gothenburg, Sweden	04/2009
Multiple Myeloma: A "Decade of Progress" Medical Grand Rounds at RUSH Chicago, Illinois	04/2009
Anti-angiogenic therapies for Multiple Myeloma International Myeloma Workshop 2009 Washington, District of Columbia	03/2009
Improving Outcomes in Multiple Myeloma: Optimizing Induction Therapy in the Transplant Setting Massachusetts General Hospital Boston, Massachusetts	02/2009
Therapeutic Interventions to Prevent Progression of MGUS to Multiple Myeloma AACR Cancer Prevention Meeting 2008 Washington, District of Columbia	11/2008
Prognostic Factors and Staging system in Multiple Myeloma San Juan, Puerto Rico	10/2008
Can novel agents replace autologous stem cell transplantation (HDT) in myeloma? Cascais, Portugal	03/2008
Novel Therapies for Multiple Myeloma American Society of Hematology Annual Meeting Atlanta, Georgia	12/2005
Oral	
Weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients with relapsed and/or refractory multiple myeloma (MM): results from a phase 1 dose-escalation study American Society of Hematology Annual Meeting	12/2011
Phase 1 Trial of Sorafenib and Everolimus In Patients with Lymphoma or Multiple Myeloma American Society of Hematology Annual Meeting	12/2010

Novel Three- and Four-Drug Combination Regimens of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Previously Untreated Multiple Myeloma: Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study American Society of Hematology Annual Meeting	12/2010
Myeloma - Biology and Pathophysiology Session American Society of Hematology Annual Meeting	12/2010
Changes in Serum Free Light Chain Rather Than Intact Monoclonal Immunoglobulin Levels Predict Outcome with Therapy in Patients with Light Chain Amyloidosis American Society of Hematology Annual Meeting	12/2009
Novel Three- and Four-Drug Combinations of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Newly Diagnosed Multiple Myeloma: Encouraging Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study American Society of Hematology Annual Meeting	12/2009
Allogeneic Stem Cell Transplantation (SCT) for Multiple Myeloma (MM) - What Has Changed? : A CIBMTR Analysis From 1989 - 2005 American Society of Hematology Annual Meeting	12/2009
Novel Agents for Initial Therapy of Multiple Myeloma: Comparable Results with Continued Initial Therapy and Delayed Transplantation at Relapse Versus Early Transplantation American Society of Hematology Annual Meeting	12/2009
Safety and Efficacy of Novel Combination Therapy with Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide in Newly Diagnosed Multiple Myeloma: Initial Results from the Phase I/II Multi-Center EVOLUTION Study American Society of Hematology Annual Meeting	12/2008
Phase II Trial of Lenalidomide (Revlimid™) with Cyclophosphamide and Dexamethasone (RCd) for Newly Diagnosed Myeloma American Society of Hematology Annual Meeting	12/2008
Comparable Outcomes in Secretory (SM) Versus Non-Secretory (NSM) Multiple Myeloma (MM) with Autologous Hematopoietic Stem Cell Transplantation (AuHCT) American Society of Hematology Annual Meeting	12/2007
Phase II Trial of Lenalidomide, Cyclophosphamide, and Dexamethasone (CRd) for Newly Diagnosed Myeloma American Society of Hematology Annual Meeting	12/2007
Serum Uric Acid Is a Novel Prognostic Factor in Patients with Primary Systemic Amyloidosis American Society of Hematology Annual Meeting	12/2007
Prognostic Value of Serum Lactate Dehydrogenase (LDH) in Patients with Primary Systemic Amyloidosis Undergoing Stem Cell Transplantation American Society of Hematology Annual Meeting	12/2007
Improving Survival in Multiple Myeloma: Impact of Novel Therapies American Society of Hematology Annual Meeting	12/2007
Analysis of Outcome after Autologous Stem Transplantation in Patients with Newly Diagnosed Myeloma: Comparison of Different Induction Regimens. American Society of Hematology Annual Meeting	12/2006

Prognostic Value of Bone Marrow Angiogenesis in Patients with Multiple Myeloma Undergoing High Dose Therapy American Society of Hematology Annual Meeting San Diego, California	12/2003
Prognostic Value of Circulating Plasma Cells in Monoclonal Gammopathy of Undetermined Significance American Society of Hematology Annual Meeting San Diego, California	12/2003
ENMD-0995 (S 3-APG), a Novel Thalidomide Analogue, Has Promising Clinical Activity for Patients with Relapsed Refractory Multiple Myeloma. Preliminary Results of a Phase I Clinical Trial American Society of Hematology Annual Meeting San Diego, California	12/2003
Autologous Peripheral Blood Stem Cell Transplantation for Primary Refractory Multiple Myeloma IXth International Multiple Myeloma Workshop Salamanca, Spain	05/2003
Single Agent Dexamethasone for Induction in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplants IXth International Multiple Myeloma Workshop Salamanca, Spain	05/2003
Peripheral Blood Stem Cell Transplantation for Primary Systemic Amyloidosis with Cardiac Involvement American Society of Hematology Annual Meeting Philadelphia, Pennsylvania	12/2002
Acquired von Willebrand Syndrome (AVWS) in Chronic Myeloproliferative Disorders (MPD): Clinical and Laboratory Features, and Response to Therapy American Society of Hematology Meeting	12/2002
Expression of VEGF and its Receptors by Myeloma Cells Plenary Session II, American Federation of Medical Research Annual Meeting Baltimore, Maryland	04/2002
Primary Cardiac Sarcomas-A Single Institution Experience American Society of Clinical Oncology Meeting San Francisco, California	05/2001
Splenectomy in Chronic Immune Thrombocytopenia and Salvage Therapies for Post-splenectomy Relapses International Society of Hematology Annual Meeting Toronto, Ontario, Canada	08/2000
Acquired von Willebrand's Disease: A Single Institution Experience International Hemophilia Congress Montreal, Quebec, Canada	06/2000
Natural History of Acute Portal Vein and Acute Mesenteric Venous Thrombosis Poster Digestive Diseases Week San Diego, California	05/2000
Thrombocytopenia During Epoprostenol Infusion for Primary Pulmonary Hypertension: Is there a Relation to Dose? American Society of Hematology Meeting	12/1998
Cyclosporine Therapy in Aplastic Anemia Annual Conference of Association of Physicians of India	06/1994

A Clinical Profile of Chronic Lymphocytic Leukemia 06/1993
Annual Conference of the Association of Physicians of India

Poster

Phase I trial of a novel combination of an HDAC inhibitor (LBH589) and an mTOR inhibitor (RAD001) in lymphoid and plasma cell malignancies 12/2011
American Society of Hematology Annual Meeting

Phase II Trial of Intravenously Administered AMD3100 (Plerixafor) for Stem Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Following a Lenalidomide-based Initial Therapy 12/2011
American Society of Hematology Annual Meeting

Differences in patterns of treatment and outcome among patients with relapsed refractory multiple myeloma from United States, Europe and Asia 12/2011
American Society of Hematology Annual Meeting

Improvement In Renal Function In Newly Diagnosed Myeloma Improves Survival, but Still Remains Inferior to Those with Normal Renal Function 12/2010
American Society of Hematology Annual Meeting

Recent Improvements In Survival In Light Chain Amyloidosis and the Importance of An Early Mortality Risk Score 12/2010
American Society of Hematology Annual Meeting

Treatment patterns and outcome among patients with multiple myeloma relapsing and or refractory to bortezomib and immunomodulatory drugs: A multicenter International Myeloma Working Group study 06/2010
American Society of Clinical Oncology Annual Meeting

Natural History of Multiple Myeloma Relapsing After Therapy with IMiDs and Bortezomib: A Multicenter International Myeloma Working Group Study 12/2009
American Society of Hematology Annual Meeting

A Novel Prognostic Staging System for Light Chain Amyloidosis (AL) Incorporating Markers of Plasma Cell Burden and Organ Involvement 12/2009
American Society of Hematology Annual Meeting

A Phase II Trial of Lenalidomide, Cyclophosphamide and Dexamethasone (RCD) in Patients with Light Chain Amyloidosis 12/2009
American Society of Hematology Annual Meeting

Stem Cell Mobilization Following Initial Therapy with Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma 12/2008
American Society of Hematology Annual Meeting

Response Duration with Initial Therapy Is a Major Predictor of Overall Survival in Multiple Myeloma: Analysis from Multiple Phase III ECOG Clinical Trials 12/2008
American Society of Hematology Annual Meeting

Association of High Levels of Free Light Chain and the Presence of Igh Translocations in Multiple Myeloma and Prognostic Implications 12/2008
American Society of Hematology Annual Meeting

Serum Immunoglobulin Free Light Chain in Primary Amyloidosis: Prognostic Value and Correlations with Clinical Features 12/2008
American Society of Hematology Annual Meeting

Normalization of the Serum Free Light Chain (FLC) Ratio Is Associated with Superior Overall Survival among Myeloma Patients Achieving Immunofixation Negative State: Results Support Incorporation of Serum FLC Ratio in Stringent CR Definition 12/2008
American Society of Hematology Annual Meeting

Delayed Platelet Engraftment and Outcome of Stem Cell Transplant for Multiple Myeloma: Possible Microenvironment Effect? American Society of Hematology Annual Meeting	12/2007
Pegylated Liposomal Doxorubicin (PLD) in Combination with Bortezomib (B) May Provide Therapeutic Advantage for High-Risk Multiple Myeloma Patients Relapsing within 12 Months of Stem Cell Transplant American Society of Hematology Annual Meeting	12/2007
Outcome after Autologous Stem Cell Transplantation for Multiple Myeloma in Patients with Preceding Plasma Cell Disorders American Society of Hematology Annual Meeting	12/2007
Effect of Thrombotic Events on Overall Survival in Patients with Newly Diagnosed Myeloma: Analysis from a Randomized Phase III Trial of Thalidomide Plus Dexamethasone Versus Dexamethasone in Newly Diagnosed Multiple Myeloma (E1A00) American Society of Hematology Annual Meeting	12/2007
Comparison of Serum Free Light Chain Levels and 24 Hour Urinary Monoclonal Protein Secretion in Patients with Myeloma: Concordant Changes with Response to Therapy. American Society of Hematology Annual Meeting	12/2006
Mi-63, a Small Molecule Inhibitor of MDM2-p53 Interaction, Has Significant In Vitro Activity in Multiple Myeloma. American Society of Hematology Annual Meeting	12/2006
Epigallocatechin-3-Gallate (EGCG), a Polyphenol Extracted from Green Tea, Has Significant In Vitro Activity Against Myeloma Cells. American Society of Hematology Annual Meeting	12/2006
Autologous Stem Cell Transplantation for Multiple Myeloma in Patients with Reduced Renal Function: A Matched Set Comparison. American Society of Hematology Annual Meeting	12/2006
Autologous Stem Cell Transplantation Provides Additional Cytoreduction Following Induction Therapy in Multiple Myeloma. American Society of Hematology Annual Meeting	12/2006
High Incidence of IgH Translocations in Monoclonal Gammopathies with Abnormal Free Light Chain Levels. American Society of Hematology Annual Meeting	12/2006
Comparison of Three Different Induction Regimens in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Poster Discussion American Society of Clinical Oncology Annual Meeting Chicago, Illinois	05/2003
Effect of Allogeneic Stem Cell Transplantation on Bone Marrow (BM) Angiogenesis in Chronic Myelogenous Leukemia Poster American Society of Bone Marrow Transplantation Annual Conference Keystone, Colorado	02/2003
Lymphocyte Recovery after Allogeneic Stem Cell Transplantation: Comparison of Bone Marrow and Peripheral Blood Stem Cell Transplantation Poster American Society of Bone Marrow Transplantation Annual Conference Keystone, Colorado	02/2003

Prognostic Value of Angiogenesis in Solitary Plasmacytoma Poster American Society of Hematology Annual Meeting Philadelphia, Pennsylvania	12/2002
Serum Syndecan (CD138) Levels Are Increased in Patients with Symptomatic Multiple Myeloma Compared to Normal Controls, MGUS, and Smoldering Myeloma Poster American Society of Hematology Annual Meeting Philadelphia, Pennsylvania	12/2002
Plasma Cell Labeling Index: Comparison of Peripheral Blood vs Bone Marrow Myeloma Plasma Cells Poster American Society of Hematology Annual Meeting Philadelphia, Pennsylvania	12/2002
Single Agent Dexamethasone for Induction in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplants Poster American Society of Hematology Annual Meeting Philadelphia, Pennsylvania	12/2002
Natural History of Relapsed Multiple Myeloma Poster American Society of Hematology Annual Meeting Philadelphia, Pennsylvania	12/2002
Expression of Angiogenic Cytokines by Plasma Cells: A Comparison of MGUS, Smoldering Myeloma and Newly Diagnosed Symptomatic Myeloma Poster American Society of Hematology Annual Meeting Philadelphia, Pennsylvania	12/2002
Autologous Peripheral Blood Stem Cell Transplantation for Primary Refractory Multiple Myeloma Poster American Society of Hematology Annual Meeting Philadelphia, Pennsylvania	12/2002
Bcl-2 Over-Expression Results in Decreased Measles Virus Mediated Cytotoxicity in Lymphoma Cell Lines Poster American Society of Hematology Annual Meeting Philadelphia, Pennsylvania	12/2002
Hepatic Venous Outflow Obstruction Among Patients With Chronic Myeloproliferative Disorders Poster AASLD Single Topic Conference :Hepatic Vascular Diseases: Hepatic Venocclusive Disease and Hepatic Vascular Thrombosis Atlanta, Georgia	03/2002
Lymphocyte Recovery After Allogeneic Bone Marrow Transplantation Predicts Risk Of Relapse In Acute Lymphoblastic Leukemia Poster American Society of Bone Marrow Transplantation Annual Conference Orlando, Florida	02/2002

- Charcoal Hemofiltration For Hepatic Veno-Occlusive Disease After Hematopoietic Stem Cell Transplantation 12/2001
Poster
American Society of Hematology Annual Meeting
Orlando, Florida
- Early Prediction of Relapse after Allogenic Transplantation for AML 12/2000
American Society of Hematology Annual Meeting
San Francisco, California
- High Incidence of Gastrointestinal Bleeding after Autologous Transplantation for Primary Systemic Amyloidosis 12/2000
Poster
American Society of Hematology Annual Meeting
San Francisco, California
- Omission of Day +11 Methotrexate for Graft-versus-host Disease Prophylaxis after Allogenic BMT Increases the Risk of Severe Acute Graft-versus-host Disease 12/2000
Poster
American Society of Hematology Annual Meeting
San Francisco, California
- Bone Marrow Angiogenesis in Multiple Myeloma : Effect of Therapy and Prognostic Value 12/2000
Poster
American Society of Hematology Annual Meeting
San Francisco, California
- A 25 Year Single Institutional Experience with Autoimmune Factor VIII Inhibitors (Acquired Hemophilia) 12/2000
Poster
American Society of Hematology Annual Meeting
San Francisco, California
- Prophylaxis of GVHD with Cyclosporine-Prednisone is Associated with an Increased Risk of Chronic GVHD 02/1999
Poster
American Society of Bone Marrow Transplantation Annual Conference
Keystone, Colorado

Regional

Invited

- Emerging Targets and Therapies in Myeloma 10/2011
9th Annual LLS Multiple Myeloma Conference
Milwaukee
- Advances in the management of multiple myeloma 03/2011
Hackensack University Medical Center
Hackensack, New Jersey
- Optimal Strategies for Nontransplantation Candidates 01/2011
VA Medical Center
Hackensack, New Jersey
- Angiogenesis in Myeloma: Role of Microenvironment in Cancer 11/2010
University of Georgia
Athens, Georgia

Tumor Microenvironment in Myeloma: Role of Angiogenesis 4th Mayo Clinic Angiogenesis Symposium Mackinaw, Michigan	08/2010
ASH 2009 Updates: Myeloma and Amyloidosis 7th Annual Mayo Clinic Hematology Review Minneapolis, Minnesota	01/2010
An Update on the Treatment of Multiple Myeloma and Amyloidosis 20th Annual Mayo Clinic Hematology/Oncology Reviews Amelia Island, Florida	06/2009
Stem Cell Transplantation for Myeloma Invited lecture for fellows Buffalo, New York	03/2007

Visiting Professorships

Visiting Professorships

Angiogenesis in Myeloma: Role of Microenvironment in Cancer University of Georgia at Athens Athens, Georgia	11/2010
Multiple Myeloma: Treatment and Management Strategies 2009 2009 Visiting Professorships for Hematology/ Oncology fellows:Multiple Myeloma Buffalo, New York	07/2009

Clinical Practice, Interests, and Accomplishments

Epidemiology of Monoclonal gammopathies Risk stratification in multiple myeloma and high risk myeloma Prognosis and treatment of Light chain amyloidosis Stem cell transplantation

Research Interests

Study of Multiple Myeloma biology with focus on angiogenesis and bone marrow microenvironment, Development of novel targeted therapeutic agents for multiple myeloma,

Phase 1 and 2 clinical trials in myeloma, Biology of High risk myeloma, Clinical Bone marrow Transplantation Research,

Research Grants Awarded

Active Grants

Federal

Principal Investigator	Specialized Program of Research Excellence in Medicine - Career Development Award. Funded by National Cancer Institute. (P50 CA 100707 (CDA))	07/01/2004 - 06/30/2007
Program Director / Principal Investigator	Onset and biomarkers for progression of monoclonal gammopathies. Funded by National Cancer Institute. (R01 CA 168762)	07/17/2012 - 04/30/2017
Program Director / Principal Investigator	Translation of Novel Therapeutic Targets in Multiple Myeloma. Funded by National Cancer Institute. (R01 CA 167511)	01/22/2013 - 12/31/2017
Program Director / Principal Investigator	The Role of Cereblon Pathways in Myeloma. Funded by National Cancer Institute. (R01 CA 183968)	04/01/2014 - 03/31/2019

Program Director / Principal Investigator	Prevalence and Progression of Monoclonal Gammopathies. Funded by National Cancer Institute. (R01 CA 107476)	04/08/2014 - 02/28/2019
Program Director / Principal Investigator	MN Partnership for Biotechnology - Predicting Response and Resistance to Proteasome Inhibitors in Multiple Myeloma. Funded by Minnesota Partnership for Biotechnology and Medical Genomics. (P004925901)	02/01/2015 - 01/31/2017
Program Director / Principal Investigator	Mayo Clinic Multiple Myeloma SPORE Project 4; "Clonal Evolution in Multiple Myeloma". Funded by National Cancer Institute. (P50 CA 186781)	09/01/2015 - 08/31/2020
Co-Investigator	Influence of germ line genetic variation on myeloma progression and survival. Funded by National Cancer Institute. (R21 CA 191896)	12/15/2014 - 11/30/2016

Foundation

Program Director / Principal Investigator	MMRC Site Investment Grant. Funded by Multiple Myeloma Research Consortium. (MMRC-2011)	01/01/2011 - 12/31/2015
Program Director / Principal Investigator	MMRF-11-001, A Prospective, Longitudinal, Observational Study in Newly Diagnosed Multiple Myeloma (MM) Patients to Assess the Relationship between Patient Outcomes, Treatment Regimens and Molecular Profiles (the "Study"). Funded by Multiple Myeloma Research Foundation. (MMRF-11-001)	06/22/2012 - 06/21/2020
Program Director / Principal Investigator	The international Myeloma Foundation for Shaji Kumar. Funded by International Myeloma Foundation.	01/01/2015 - 12/31/2016

Industry

Program Director / Principal Investigator	MC0884, "A Phase II Trial of Revlimid® and "On demand" dexamethasone dosing in Patients with Newly Diagnosed Symptomatic Multiple Myeloma". Funded by Celgene. (RV-MM-PI-0367/MC0884)	09/02/2008 - 09/01/2010
Program Director / Principal Investigator	MC0884 - Correlative work in: MC0884, "A Phase II Trial of Revlimid® and "On demand" dexamethasone dosing in Patients with Newly Diagnosed Symptomatic Multiple Myeloma". Funded by Celgene. (RV-MM-PI-0367/MC0884)	09/02/2008 - 09/01/2010
Program Director / Principal Investigator	A Phase I/II Trial of LBH589 and RAD001 in Patients with Relapsed Multiple Myeloma or Non-Hodgkin's Lymphoma in: MC0886, "A Phase I/II Study of the HDAC Inhibitor LBH589 (Panobinostat) in Combination with the mTOR inhibitor RAD001 (Everolimus) in Patients with Relapsed Non-Hodgkins Lymphoma, Hodgkin Lymphoma, or Multiple Myeloma". Funded by Novartis. (CLBH589BUS17T/MC0886)	10/01/2008 - 09/30/2010
Program Director / Principal Investigator	MMRC-020-021 in: MMRC-020-021, A Phase I/II, Multicenter, Open-label, Dose-escalation Study of Bendamustine in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma. Funded by Cephalon, Incorporated. (MMRC-020-021)	09/01/2009 - 08/31/2011

Program Director / Principal Investigator	C16005 in: C16005, An Open-Label, Dose-Escalation Ph 1/2 Study of the Oral Form of MLN9708, a Second-Gen Proteasome Inhibitor, Admin in Combination with Lenalidomide and Low-Dose Dexamethasone in Pts with Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment. Funded by Millennium Pharmaceuticals, Inc. (Protocol C16005 / Millennium Agreeemnt Number 220299)	10/01/2010 - 09/30/2013
Program Director / Principal Investigator	MCR MC1181 Phase 2 Trial of MLN9708 in Patients With Relapsed Multiple Myeloma Who Are Not Refractory to Bortezomib. Funded by Millennium Pharmaceuticals, Inc. (Protocol X16001 / MC1181 / Millennium Agmt No. 223625)	06/24/2011 - 06/23/2013
Program Director / Principal Investigator	MC1187: Phase 2 trial of retreatment with lenalidomide and dexamethasone for patients with relapsed myeloma. Funded by Celgene. (Celgene Reference # RV-MM-PI-0474)	01/08/2012 - 01/07/2015
Program Director / Principal Investigator	Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined and significance and smoldering myeloma. Funded by Janssen Research and Development, LLC.	04/01/2012 - 03/31/2014
Program Director / Principal Investigator	Replacement #2 CLGH447X2101 Escalation in: Replacement #2 CLGH447X2101, A Multi-Center, Open-Label, Dose Escalation, Phase 1 Study of Oral LGH447 in Patients with Relapsed and/or Refractory Multiple Myeloma. Funded by Novartis. (Protocol LGH447X2101)	06/01/2012 - 05/31/2015
Program Director / Principal Investigator	Replacement #2 CLGH447X2101 Expansion in: Replacement #2 CLGH447X2101, A Multi-Center, Open-Label, Dose Escalation, Phase 1 Study of Oral LGH447 in Patients with Relapsed and/or Refractory Multiple Myeloma. Funded by Novartis. (Protocol LGH447X2101)	06/01/2012 - 05/31/2015
Program Director / Principal Investigator	C16010: A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 plus Lenalidomide and Dexamethasone versus Placebo plus Lenalidomide and Dexamethasone in Adult Patients with Relapsed and/or Refractory Multiple Myeloma. Funded by Millennium Pharmaceuticals, Inc. (Protocol C16010)	09/07/2012 - 09/06/2015
Program Director / Principal Investigator	Dose Escalation M12-901: A Phase 1b Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Relapsed or Refractory Multiple Myeloma Subjects who are Receiving Bortezomib and Dexamethasone as their Standard Therapy in: Amend 1 Repl MCR 12-006410 M12-901: A Phase 1b Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Relapsed or Refractory Multiple Myeloma Subjects who are Receiving Bortezomib and Dexamethasone as their Standard Therapy. Funded by AbbVie Inc. (Protocol M12-901)	12/15/2012 - 12/14/2015
Program Director / Principal Investigator	Safety Expansion-M12-901: A Phase 1b Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Relapsed or Refractory Multiple Myeloma Subjects who are Receiving Bortezomib and Dexamethasone as their Standard Therapy in: Amend 1 Repl MCR 12-006410 M12-901: A Phase 1b Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Relapsed or Refractory Multiple Myeloma Subjects who are Receiving Bortezomib and Dexamethasone as their Standard Therapy. Funded by AbbVie Inc. (Protocol M12-901)	12/15/2012 - 12/14/2015

Program Director / Principal Investigator	MCR MC1286: Bortezomib, melphalan and low dose TBI conditioning for patients undergoing autologous stem cell transplantation for multiple myeloma. Funded by Millennium: The Takeda Oncology Company. (MC1286 / Millennium Protocol X05399)	04/01/2013 - 03/31/2018
Program Director / Principal Investigator	MC1382: Phase 1/2 trial of MLN9708 in combination with cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma in: 13-000414 MC1382: Phase 1/2 trial of MLN9708 in combination with cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Funded by Millennium Pharmaceuticals, Inc. (MC1382 / Millennium Protocol: X16009)	06/01/2013 - 05/31/2017
Program Director / Principal Investigator	Prognostic significance of Alpha 1-acid glycoprotein (AAG) in multiple myeloma. Funded by Array BioPharma, Inc.	08/01/2013 - 07/31/2014
Program Director / Principal Investigator	C16014: A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma. Funded by Millennium Pharmaceuticals, Inc. (Protocol C16014)	08/01/2013 - 07/31/2016
Program Director / Principal Investigator	MCR M13-367: A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects with Relapsed or Refractory Multiple Myeloma in: MCR M13-367 12-005388 : A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects with Relapsed or Refractory Multiple Myeloma. Funded by AbbVie Inc. (Protocol M13-367)	10/26/2013 - 10/25/2016
Program Director / Principal Investigator	Amend 1 Repl C16020 Arms A & B in: Amend 1 (Repl) C16020: An Open-Label, Phase 2 Study to Evaluate the Oral Combination of MLN9708 With Cyclophosphamide and Dexamethasone In Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment. Funded by Millennium Pharmaceuticals, Inc. (Millennium Protocol C16020 / Appendix 21)	04/01/2014 - 03/31/2017
Program Director / Principal Investigator	Amend 1 Repl C16020 Arm C in: Amend 1 (Repl) C16020: An Open-Label, Phase 2 Study to Evaluate the Oral Combination of MLN9708 With Cyclophosphamide and Dexamethasone In Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment. Funded by Millennium Pharmaceuticals, Inc. (Millennium Protocol C16020 / Appendix 21)	04/01/2014 - 03/31/2017
Program Director / Principal Investigator	Rd Arm in: Amendment #1 5476741MMY3003 (14-008926): Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed or Refractory Multiple Myeloma. Funded by Janssen Research and Development, LLC. (5476741MMY3003)	04/01/2015 - 03/31/2017
Co-Investigator	CC-5013-MM-020 in: CC-5013-MM-020, Ph III, Randomized Open-Label, 3-Arm Study to Determine Effic/Safety of CC-5013/Low-Dose Dex When Gvn to Prog Dz/18 4-Wk Cycles vs MelpH/Pred/Thal Given for 12 6-Wk Cyc in Pts w/ Prev Untr MM Who Are 65 yr or Older/Not for Stem Cell Trans. Funded by Celgene. (CC-5013-MM-020)	07/16/2007 - 07/15/2012

Co-Investigator	MC078E, "Phase I/II Study Of Lenalidomide (Revlimid), Rituximab, Cyclophosphamide, Doxorubicin, Vincristine And Prednisone (R2chop) Chemoimmunotherapy In Patients With Newly Diagnosed Diffuse Large Cell And Follicular Grade IIIA/B B Cell Lymphoma" in: MC078E Phase I/II Study Of Lenalidomide (Revlimid), Rituximab, Cyclophosphamide, Doxorubicin, Vincristine And Prednisone (R2chop) Chemoimmunotherapy In Patients With Newly Diagnosed Diffuse Large Cell And Follicular Grade IIIA/B B Cell Lymphoma. Funded by Celgene. (MC078E/RV-NHL-PI-325)	02/01/2008 - 01/31/2012
Co-Investigator	SG035-0003 in: SG035-0003, "A Pivotal Study of SGN-35 in Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma (HL)". Funded by Seattle Genetics, Inc. (SG035-0003)	01/01/2009 - 12/31/2010
Co-Investigator	CC-5013-MCL-001 in: CC-5013-MCL-001, Phase 2, Multicenter, Single-Arm, Open-Label Study To Determine The Efficacy And Safety Of Single-Agent Lenalidomide In Pts With Mantle Cell NHL Who Relapsed Or Progressed After Treatment With Bortezomib or are Refractory to Bortezomib". Funded by Celgene. (Protocol: CC-5013-MCL-001 / The)	01/05/2009 - 01/04/2012
Co-Program Director / Principal Investigator	MC088A in: MC088A, "Phase I/II Study of combination of Aurora Kinase Inhibitor MLN8237 and Bortezomib in Relapsed or Refractory Multiple Myeloma". Funded by Millennium Pharmaceuticals, Inc. (MC088A/X14003)	01/24/2009 - 01/23/2012
Co-Investigator	Amend #5 Repl Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) with Everolimus (RAD001) and Alemtuzumab: A Phase I/II Study in: Amend #5 (Repl) MC088C, Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) with Everolimus (RAD001) and Alemtuzumab: A Phase I/II Study. Funded by Novartis. (MC088C/CRAD001NUS100T)	03/01/2009 - 12/31/2017
Co-Investigator	Amendment 2 Replacement OMB110921- A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia. Funded by GlaxoSmithKline. (OMB110921)	05/01/2009 - 04/30/2011
Co-Investigator	MC0983 - PCO for CLL in: MC0983, "Phase II Trial of Pentostatin, Cyclophosphamide, and Ofatumumab For Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL)". Funded by Novartis. (MC0983 / Protocol #OFT113301)	09/01/2009 - 08/31/2012
Co-Investigator	Celgene/MC0981 in: Celgene: MC0981, A Phase I/II Clinical Trial of the mTor Inhibitor RAD001 (Everolimus) in Combination with Lenalidomide (Revlimid) for Patients with Relapsed or Refractory Lymphoid Malignancy. Funded by Celgene. (MC0981 / RV-NHL-PI-0466)	09/01/2009 - 08/31/2014
Co-Investigator	Novartis/MC0981 in: Novartis: MC0981, A Phase I/II Clinical Trial of the mTor Inhibitor RAD001 (Everolimus) in Combination with Lenalidomide (Revlimid) for Patients with Relapsed or Refractory Lymphoid Malignancy. Funded by Novartis. (MC0981 / CRAD001NUS113T)	09/01/2009 - 08/31/2014
Co-Investigator	CRAD001N2301 in: CRAD001N2301, RAD001 in Patients with DLBCL. Funded by Novartis. (CRAD001N2301)	09/01/2009 - 08/31/2014

Co-Program Director / Principal Investigator	Combined MCA/MCR/MMRC: Phase I/II Study of combination of Aurora Kinase Inhibitor MLN8237 and Bortezomib in Relapsed or Refractory Multiple Myeloma in: Phase I/II Study of combination of Aurora Kinase Inhibitor MLN8237 and Bortezomib in Relapsed or Refractory Multiple Myeloma. Funded by Millennium Pharmaceuticals, Inc. (MC088A)	12/21/2009 - 12/20/2012
Co-Investigator	PX-171-009 in: PX-171-009, A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Relapsed Multiple Myeloma. Funded by Onyx Pharmaceuticals Corporation. (Protocol PX-171-009)	08/01/2010 - 07/31/2013
Co-Investigator	MC0986 in: MC0986, "A Phase II Study of the Histone Deacetylase (HDAC) Inhibitor LBH589 (Panobinostat) in Patients with Relapsed non-Hodgkin Lymphoma". Funded by Novartis. (MC0986/CLBH589BUS59T)	11/01/2010 - 10/31/2016
Co-Investigator	A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients with Hematological Malignancies in: CIBMTR 09-PLEX: A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients with Hematological Malignancies. Funded by Genzyme Corporation. (CIBMTR PROTOCOL 09-PLEX / Genzyme Protocol #MAMO0109-2)	04/01/2013 - 03/31/2016
Co-Program Director / Principal Investigator	TED10893 Phase II in: 10-002922 MCR TED10893: A Ph 1/2 Dose Escalation Safety & PK Study of Multiple IV Administrations of a Humanized Monoclonal Antibody (SAR650984) Against CD38 In Patients with Selected CD38+ Hematological Malignancies. Funded by Sanofi Aventis. (Work Order No. 11 / Protocol No. TED10893)	01/09/2015 - 01/08/2017
Consultant	DRd Arm in: Amendment #1 54767414MMY3003 (14-008926): Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed or Refractory Multiple Myeloma. Funded by Janssen Research and Development, LLC. (5476741MMY3003)	04/01/2015 - 03/31/2017

Mayo Clinic

Program Director / Principal Investigator	Clinical outcomes and predictive factors in 17p deleted multiple myeloma. Funded by SGP - Small Grants Program	11/14/2013 - 11/13/2015
Co-Investigator	Altered metabolic pathways as a mechanism of therapeutic resistance to immunomodulators in Multiple Myeloma. Funded by Eagle Funds for Cancer Research.	06/01/2015 - 05/31/2016

Completed Grants**Federal**

Principal Investigator	Chromosomal Abnormalities in Myeloma as Detected by FISH. Funded by National Cancer Institute. (R01 CA083724)	03/2006 - 02/2008
Co-Investigator	Signal transduction inhibitor therapy for Lymphoma in: Lymphoma SPORE. Funded by National Cancer Institute. (P50 CA 97274)	07/2007 - 06/2012

Co-Investigator	Signal transduction inhibitor therapy for Lymphoma. Funded by National Cancer Institute. (R01 CA 127433)	09/2007 - 07/2014
Co-Investigator	Phase I Clinical Trials of Anticancer Agents. Funded by National Cancer Institute. (U01 CA 69912)	07/2008 - 02/2014
Co-Investigator	Prevalence and Progression of Monoclonal Gammopathies. Funded by National Cancer Institute. (R01 CA 107476)	03/2009 - 04/2014

Foundation

Program Director / Principal Investigator	National Foundation for Cancer Research: Institute for Clinical Research Excellence. Funded by National Foundation for Cancer Research.	01/2007 - 12/2009
Program Director / Principal Investigator	Targeting Vascular Endothelial Growth Factor for Treatment of Myeloma. Funded by Multiple Myeloma Research Foundation.	09/2007 - 06/2011
Program Director / Principal Investigator	Natural History of Relapsed Myeloma in: Natural History of Relapsed Myeloma and Bortezomib-Refractory Multiple Myeloma in the Era of Novel Agents. Funded by International Myeloma Foundation. (IMF-01)	04/2009 - 03/2011
Program Director / Principal Investigator	Multiple Myeloma Research COnsortium Project Coordinator. Funded by Multiple Myeloma Research Consortium. (MMRC)	10/2009 - 12/2009
Program Director / Principal Investigator	Observational Study of the Regional Variation of Clinical Outcomes and Treatment of Patients with Relapsed Multiple Myeloma. Funded by International Myeloma Foundation. (IMF-03)	07/2012 - 06/2013

Industry

Principal Investigator	Pre-clinical Evaluation of Polyclonal Rabbit Anti-Thymocyte Globulin in Multiple Myeloma. Funded by Genzyme Corporation. (GENZYME #14; 1A5554)	03/2005 - 02/2006
Program Director / Principal Investigator	Celene - #37 - Amdt #1 - CC-5013 - MM-016 - A Multicenter, Single-Arm, Open-Label Exanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects with Multiple Myeloma in: CC-5013 - MM-016 - A Multicenter, Single-Arm, Open-Label Exanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects with Multiple Myeloma. Funded by Celgene. (CC-5013-MM-016)	04/2006 - 03/2009
Principal Investigator	Preclinical/Laboratory work to investigate the biology of BLyS and APRIL in Multiple Myeloma using TACI-Ig and other drugs. Funded by ZymoGenetics, Inc. (ZYMOGENETICS #4, 1A5988)	05/2006 - 04/2008
Program Director / Principal Investigator	MC058E - A Phase II Trial of Revlimid, Cyclophosphamide and Dexamethasone in Patients with Newly Diagnosed Active Multiple Myeloma. Funded by Celgene. (RV-MM-PI-0116/MC058E)	06/2006 - 05/2009
Program Director / Principal Investigator	MC0685 - A Phase II Trial of Revlimid, Cyclophosphamide and Dexamethasone in Patients with Primary Systemic Amyloidosis. Funded by Celgene. (MC0685/RV-AMY-PI-0145)	01/2007 - 12/2009

Program Director / Principal Investigator	Laboratory Services Agreement for Protocol C05008 "Phase 1/2 Study of VELCADE (Bortezomib), Dexamethasone, and Revlimid (Lenalidomide) (VDR) versus VELCADE, Dexamethasone, Cyclophosphamide, and Revlimid (VDCR) in Subjects with Prev...". Funded by Millennium Pharmaceuticals, Inc. (Millennium Agreement No. 215153)	06/2007 - 05/2009
Program Director / Principal Investigator	C05008: "Phase 1/2 Study of VELCADE (Bortezomib), Dexamethasone, and Revlimid (Lenalidomide) (VDR) versus VELCADE, Dexamethasone, Cyclophosphamide, and Revlimid (VDCR) in Subjects with Previously Untreated Multiple Myeloma". Funded by Millennium Pharmaceuticals, Inc. (Protocol C05008 / Agreement No. 215348)	11/2007 - 10/2010
Program Director / Principal Investigator	MC078A, "A Phase I/II Study of the Sorafenib in Combination with Lenalidomide in Patients with Relapsed Multiple Myeloma". Funded by Bayer HealthCare AG. (MC078A / SR06-933)	01/2008 - 12/2010
Program Director / Principal Investigator	REPLACEMENT BUDGET - Amendment #1 - MC0687 - A Phase II Trial of Thymoglobulin and Melphalan in Patients with Relapsed Multiple Myeloma. Funded by Genzyme Corporation. (MC0687)	04/2008 - 03/2010
Program Director / Principal Investigator	In vitro effects of pomalidomide in primary Myeloma cells obtained from patients with relapsed Myeloma who are refractory to lenalidomide in: SRA 47 - In vitro effects of pomalidomide in primary Myeloma cells obtained from patients with relapsed Myeloma who are refractory to lenalidomide. Funded by Celgene.	01/2009 - 12/2009
Program Director / Principal Investigator	MC0889 in: MC0889, "Phase II trial of AMD3100 (Plerixafor) for stem cell mobilization in patients with multiple myeloma undergoing autologous stem cell transplantation following a lenalidomide based initial therapy". Funded by Genzyme Corporation. (MC0889)	01/2009 - 01/2010
Program Director / Principal Investigator	TAK-901_101: Phase 1 Study of TAK-901 in Subjects With Advanced Hematologic Malignancies. Funded by Millennium Pharmaceuticals, Inc. (Protocol TAK 901-101)	09/2009 - 08/2010
Program Director / Principal Investigator	C16004 in: C16004 "An Open Label, Dose Escalation, Phase I Study Evaluating the Safety and Tolerability of Weekly Dosing of the Oral Form of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients with Relapsed and Refractory Multiple Myeloma". Funded by Millennium Pharmaceuticals, Inc. (Protocol C16004 / Appendix Agmt #219618)	10/2009 - 09/2011
Program Director / Principal Investigator	MC0985: Phase II study of bortezomib, cyclophosphamide and dexamethasone in patients with primary systemic (light chain amyloidosis) in: MC0985: Phase II study of bortezomib, cyclophosphamide and dexamethasone in patients with primary systemic (light chain amyloidosis). Funded by Millennium Pharmaceuticals, Inc. (MC0985 / Protocol X05306 / Agreement No. 220519)	12/2009 - 12/2012
Program Director / Principal Investigator	Pilot study to assess the clinical outcomes of patients with newly diagnosed multiple myeloma receiving frontline bortezomib-containing three-drug regimens. Funded by Millennium.	03/2013 - 02/2014

Program Director / Principal Investigator	MC1287: A Phase 2 Trial of Carfilzomib Consolidation Following Autologous Stem Cell Transplantation for Multiple Myeloma (CARAMEL 2). Funded by Onyx Pharmaceuticals Corporation. (MC1287 / Protocol 117659 / Onyx Reference Number: IST-CAR-551)	03/2013 - 02/2019
Co-Investigator	TRM-1-MM01 - A Phase I , Open-label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of TRM-1 (Fully-human Monoclonal Antibody to the Trail-R1) in Subjects with Multiple Myeloma. Funded by Human Genome Sciences, Inc. (HGS #4; 1A4824)	04/2003 - 03/2006
Co-Investigator	MOZ00607 in: MOZ00607, "Expanded Access Study of Plerixafor and G-CSF for the Mobilization and Collection of Peripheral Blood Stem Cells for Autologous Stem Cell Transplantation in Patients with Non-Hodgkin's Lymphoma, Hodgkin's Disease or Multiple Myeloma". Funded by Genzyme Corporation. (MOZ00607)	07/2007 - 07/2009
Co-Investigator	A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Prochymal (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) Infusion in Combination with Corticosteroids for the Treatment of diagnosed Acute GVHD in: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Prochymal (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) Infusion in Combination with Corticosteroids for Treatment of diagnosed Acute GVHD (Protocol 265). Funded by Osiris Therapeutics, Inc. (Protocol 265)	12/2007 - 11/2008
Co-Investigator	101MY201, "A Phase 1/2, Two Arm, Dose Finding Study of Natalizumab for the Treatment of Subjects with Relapsed or Refractory Multiple Myeloma". Funded by Biogen Idec. (101MY201)	04/2008 - 03/2011
Co-Investigator	MC0882: A Phase 2 Study of Lenalidomide (Revlimid), Rituximab, Cyclophosphamide and Dexamethasone (R2-CD) for symptomatic untreated low grade non-Hodgkin lymphoma. Funded by Celgene. (RV-NHL-PI-0336/MC0882)	05/2008 - 04/2013
Co-Investigator	CC-5013-NHL-005 in: CC-5013-NHL-005, "A Phase II, Multicenter, Single-Arm, Open-Label Study To Evaluate The Safety And Efficacy Of Lenalidomide (Revlimid®) In Combination With Dexamethasone In Subjects With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma". Funded by Celgene. (CC-5013-NHL-005)	05/2008 - 04/2010
Co-Investigator	LS0382 - CTI in: LS0382, A Phase I Trial of CpG 7909, Rituximab Immunotherapy, and Y-90 Zevalin Radioimmunotherapy For Patients with Previously Treated CD20+ Non-Hodgkin Lymphoma (CTI). Funded by Spectrum Pharmaceuticals, Inc. (LS0382)	05/2008 - 04/2013
Co-Investigator	LS0382 - Pfizer in: LS0382, A Phase I Trial of CpG 7909, Rituximab Immunotherapy, and Y-90 Zevalin Radioimmunotherapy For Patients with Previously Treated CD20+ Non-Hodgkin Lymphoma (Pfizer). Funded by Pfizer Inc. (Pfizer Tracking # GA8501YD/LS0382)	05/2008 - 04/2013

Co-Investigator	MC0885, Rev/Dex in MM patients with impaired renal function in: MC0885, A Phase I/II Study of the Tolerability of Lenalidomide and Low Dose Dexamethasone in Multiple Myeloma Patients with Impaired Renal Function. Funded by Celgene. (RV-MM-PI-0394/MC0885)	08/2008 - 07/2012
Co-Investigator	CRAD001N2201, "An Open-Label, Single-Arm Phase II Study Of RAD001 In Patients With Refractory Mantle Cell Lymphoma". Funded by Novartis. (CRAD001N2201)	08/2008 - 07/2010
Co-Investigator	CLBH589E2214, Panobinostat in Hodgkin's Lymphoma in: CLBH589E2214, "A Phase II Study Of Oral Panobinostat In Patients W/ Relapsed/Refractory Classical Hodgkin's Lymphoma After Failure Of Chemotherapy W/ Autologous Stem Cell Transfusion And A Gemcitabine/Vinorelbine/Vinblastine-Containing Treatment Regimen". Funded by Novartis. (LBH589E2214)	10/2008 - 09/2010
Co-Investigator	SG035-0004 in: SG035-0004, "A Pivotal Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma (ALCL)". Funded by Seattle Genetics, Inc. (SG035-0004)	01/2009 - 12/2010
Co-Investigator	C-935788-017 in: C-935788-017, "Phase II, Multicenter, Simon Two-Stage Study of R788 in Patients with Relapsed or Refractory T-Cell Lymphoma". Funded by Rigel Pharmaceuticals, Inc. (C-935788-017)	01/2009 - 12/2010
Co-Investigator	CC-4047-MM-002 in: CC-4047-MM-002, A Phase 1/2 Multi-center, Rand, Open Label Dose Esc Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of CC-4047 Alone or in Combination w/Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma Who... Funded by Celgene. (CC-4047-MM-002)	03/2009 - 02/2014
Co-Investigator	A Phase I/IIa randomized, observer-blind, placebo controlled, multicenter study to evaluate the safety and immunogenicity of the GSK Biologicals? herpes zoster vaccine. Funded by GlaxoSmithKline. (110258/ETR (Zoster-001 PRI))	05/2009 - 04/2011
Co-Investigator	Amendment #1, Replacement: Fx1B-201, " The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients with V122I or Wild-Type TTR Amyloid Cardiomyopathy". Funded by FoldRx. (Fx1B-201)	11/2009 - 10/2010
Co-Investigator	SGN75-001 Schedule A in: A Phase I open label dose escalation study to evaluate the safety and tolerability of SGN-75 in patients with CD70-positive relapsed or refractory non-hodgkins lymphoma or metastatic renal cell carcinoma. Funded by Seattle Genetics, Inc. (Protocol SGN75-001)	11/2009 - 11/2011
Co-Investigator	SGN75-001 Schedule B in: A Phase I open label dose escalation study to evaluate the safety and tolerability of SGN-75 in patients with CD70-positive relapsed or refractory non-hodgkins lymphoma or metastatic renal cell carcinoma. Funded by Seattle Genetics, Inc. (Protocol SGN75-001)	11/2009 - 11/2011

Co-Investigator	CNTO328MCD2001 in: CNTO328MCD2001, A Randomized, Double blind, Placebo controlled Study to Assess the Efficacy and Safety of CNTO 328 plus Best Supportive Care Compared With Best Supportive Care in Subjects With Multicentric Castleman's Disease. Funded by Janssen Research and Development, LLC. (CNTO328MCD2001)	12/2009 - 12/2012
Co-Investigator	Replacement Amendment #1 CRAD001NUS65: An Open-label, Single-arm Phase II Study of RAD001 in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma in: Replacement - Amendment #1 CRAD001NUS65: An Open-label, Single-arm Phase II Study of RAD001 in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma. Funded by Novartis. (CRAD001NUS65)	01/2010 - 12/2012
Co-Investigator	HGS1029-C1080 in: HGS1029-C1080, A Phase I, Multi-Center, Open-Label, Dose-Escalation Study of HGS1029 in Subjects with Relapsed or Refractory B-Cell Neoplasms: Chronic Lymphocytic Leukemia/Small Cell Lymphocytic Lymphoma or Non-Hodgkin's Lymphoma. Funded by Human Genome Sciences, Inc. (HGS1029-C1080)	01/2010 - 12/2011
Co-Investigator	SGN35-009 in: SGN35-009, "A Phase 1 Dose Escalation Safety Study of Combination Therapy with ABVD and Brentuximab Vedotin as Frontline Therapy in Patients with Hodgkin Lymphoma". Funded by Seattle Genetics, Inc. (SGN35-009)	01/2010 - 12/2011
Co-Investigator	P276-00-23-08 in: P276-00-23-08, "Single-Arm, Open-Label, Multicenter Phase II Study to Evaluate the Efficacy and Safety of P276-00 in Patients With Relapsed and/or Refractory Mantle Cell Lymphoma". Funded by Piramal Life Sciences Limited. (P276-00/23/08)	03/2010 - 02/2012
Co-Investigator	M06-814, "A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics and Efficacy of ABT-263 in Subjects with Relapsed or Refractory Lymphoid Malignancies". Funded by Abbott Laboratories. (Protocol M06-814)	04/2010 - 03/2012
Co-Investigator	CTKI258A2204 in: CTKI258A2204, "A Phase II, Multi-Center, Non-Randomized, Open-Label Study of TK1258 in Patients With Relapsed or Refractory Multiple Myeloma, Who Are With or Without t(4;14) Translocation". Funded by Novartis. (CTKI258A2204)	06/2010 - 05/2012
Co-Investigator	CLBH589E2301 in: CLBH589E2301, "A Phase III Randomized, Double Blind, Placebo Controlled Multi-Center Study Of Panobinostat For Maintenance Of Response In Patients With Hodgkin's Lymphoma Who Are At Risk For Relapse After High Dose Chemotherapy & ASCT". Funded by Novartis. (CLBH589E2301)	06/2010 - 05/2015
Co-Investigator	LS1084, "Early Treatment of High Risk Chronic Lymphocytic Leukemia with Alemtuzumab, Rituximab, and PGG Beta Glucan" in: LS1084 Early Treatment of High Risk Chronic Lymphocytic Leukemia with Alemtuzumab, Rituximab, and PGG Beta Glucan. Funded by Biothera, Inc. (LS1084)	09/2010 - 08/2013

Co-Investigator	IM-T-hA20/90Y-hLL2-01 Veltuzumab/90Y-Epratuzumab Tetraxetan in NHL in: IM-T-hA20/90Y-hLL2-01 Phase I/II Study of Veltuzumab Combined with 90Y-Epratuzumab Tetraxetan in Patients with Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma. Funded by Immunomedics. (Protocol IM-T-hA20/90Y-hLL2-01)	02/2011 - 02/2013
-----------------	--	-------------------

Mayo Clinic

Principal Investigator	Evaluation of bcl2 small molecule in myeloma, funded by Heme Malignancy Program. Funded by Other Mayo.	05/2005 - 04/2006
Principal Investigator	Vascular Endothelial Growth Factor (VEGF) As A Therapeutic Target In Multiple Myeloma. Funded by Mayo CR20 Funding.	10/2005 - 12/2008
Program Director / Principal Investigator	Induction of bone marrow angiogenesis is a mechanism of disease progression and resistance in multiple myeloma. Funded by Development - Gifts from benefactors.	02/2011 - 01/2014

Bibliography

Peer-reviewed Articles

1. Cordes S, Gertz MA, Buadi FK, Lin Y, Lacy MQ, Kapoor P, **Kumar SK**, McCurdy A, Dispenzieri A, Dingli D, Hayman SR, Hogan WJ, Pruthi RK. Autologous stem cell transplantation in immunoglobulin light chain amyloidosis with factor X deficiency. *Blood Coagul Fibrinolysis*. 2016 Jan; 27(1):101-8.
2. Mitra AK, Mukherjee UK, Harding T, Jang JS, Stessman H, Li Y, Abyzov A, Jen J, **Kumar S**, Rajkumar V, Van Ness B. Single-cell analysis of targeted transcriptome (SCATome) predicts drug sensitivity of single cells within human myeloma tumors. *Leukemia*. 2015 Dec 29.
3. Chng WJ, Chung TH, **Kumar S**, Usmani S, Munshi N, Avet-Loiseau H, Goldschmidt H, Durie B, Sonneveld P. Gene signature combinations improve prognostic stratification of multiple myeloma patients. *Leukemia*. 2015 Dec 16.
4. Kourelis TV, Buadi FK, Gertz MA, Lacy MQ, **Kumar SK**, Kapoor P, Go RS, Lust JA, Hayman SR, Rajkumar V, Zeldenrust SR, Russell SJ, Dingli D, Lin Y, Leung N, Hwa YL, Gonsalves W, Kyle RA, Dispenzieri A. Risk factors for and outcomes of patients with POEMS syndrome who experience progression after first line treatment. *Leukemia*. 2015 Dec 16.
5. Giralt S, Garderet L, Durie B, Cook G, Gahrton G, Bruno B, Hari P, Lokhorst H, McCarthy P, Krishnan A, Sonneveld P, Goldschmidt H, Jagannath S, Barlogie B, Mateos M, Gimsing P, Sezer O, Mikhael J, Lu J, Dimopoulos M, Mazumder A, Palumbo A, Abonour R, Anderson K, Attal M, Blade J, Bird J, Cavo M, Comenzo R, de la Rubia J, Einsele H, Garcia-Sanz R, Hillengass J, Holstein S, Johnsen HE, Joshua D, Koehne G, **Kumar S**, Kyle R, Leleu X, Lonial S, Ludwig H, Nahi H, Nooka A, Orłowski R, Rajkumar V, Reiman A, Richardson P, Riva E, San Miguel J, Tureson I, Usmani S, Vesole D, Bensinger W, Qazilbash M, Efebera Y, Mohty M, Gasparreto C, Gajewski J, LeMaistre CF, Bredeson C, Moreau P, Pasquini M, Kroeger N, Stadtmauer E. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. *Biol Blood Marrow Transplant*. 2015 Dec; 21(12):2039-51. Epub 2015 Sep 30
6. Uy GL, Costa LJ, Hari PN, Zhang MJ, Huang JX, Anderson KC, Bredeson CN, Callander NS, Cornell RF, Perez MA, Dispenzieri A, Freytes CO, Gale RP, Garfall A, Gertz MA, Gibson J, Hamadani M, Lazarus HM, Kalaycio ME, Kamble RT, Kharfan-Dabaja MA, Krishnan AY, **Kumar SK**, Kyle RA, Landau HJ, Lee CH, Maiolino A, Marks DI, Mark TM, Munker R, Nishihori T, Olsson RF, Ramanathan M, Rodriguez TE, Saad AA, Savani BN, Schiller GJ, Schouten HC, Schriber JR, Scott E, Seo S, Sharma M, Ganguly S, Stadtmauer EA, Tay J, To LB, Vesole DH, Vogl DT, Wagner JL, Wirk B, Wood WA, D'Souza A. Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation. *Bone Marrow Transplant*. 2015 Dec; 50(12):1513-8. Epub 2015 Aug 24.
7. Zand L, Nasr SH, Gertz MA, Dispenzieri A, Lacy MQ, Buadi FK, **Kumar S**, Kyle RA, Ferverza FC, Sethi S, Dingli D, Rajkumar SV, Kapoor P, McCurdy A, Leung N. Clinical and prognostic differences among patients with light chain deposition disease, myeloma cast nephropathy and both. *Leuk Lymphoma*. 2015 Dec; 56(12):3357-64. Epub 2015 May 12
8. Leung N, **Kumar SK**, Glavey SV, Dispenzieri A, Lacy MQ, Buadi FK, Hayman SR, Dingli D, Kapoor P, Zeldenrust SR, Russell SJ, Lust JA, Hogan WJ, Rajkumar SV, Gastineau DA, Kourelis TV, Lin Y, Gonsalves WI, Go RS, Gertz MA. The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation. *Nephrol Dial Transplant*. 2015 Nov 30.
9. D'Souza A, Dispenzieri A, Wirk B, Zhang MJ, Huang J, Gertz MA, Kyle RA, **Kumar S**,

Comenzo RL, Peter Gale R, Lazarus HM, Savani BN, Cornell RF, Weiss BM, Vogl DT, Freytes CO, Scott EC, Landau HJ, Moreb JS, Costa LJ, Ramanathan M, Callander NS, Kamble RT, Olsson RF, Ganguly S, Nishihori T, Kindwall-Keller TL, Wood WA, Mark TM, Hari P. Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study. *J Clin Oncol*. 2015 Nov 10; 33(32):3741-9. Epub 2015 Sep 14.

10. Majithia N, Vincent Rajkumar S, Lacy MQ, Buadi FK, Dispenzieri A, Gertz MA, Hayman SR, Dingli D, Kapoor P, Hwa L, Lust JA, Russell SJ, Go RS, Kyle RA, **Kumar SK**. Outcomes of primary refractory multiple myeloma and the impact of novel therapies. *Am J Hematol*. 2015 Nov; 90(11):981-5. Epub 2015 Oct 06.
11. Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Djulbegovic B, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Krishnan AY, **Kumar SK**, Liedtke M, Lunning M, Raje N, Singhal S, Smith C, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R. Multiple myeloma, version 2.2016. *J. Natl. Compr. Cancer Netw*. 2015 Nov; 13(11):1398-435.
12. Kaufman GP, Gertz MA, Dispenzieri A, Lacy MQ, Buadi FK, Dingli D, Hayman SR, Kapoor P, Lust JA, Russell S, Go RS, Hwa YL, Kyle RA, Rajkumar SV, **Kumar SK**. Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma. *Leukemia*. 2015 Oct 21.
13. Binder M, Rajkumar SV, Gertz MA, Lacy MQ, Dispenzieri A, Buadi FK, Dingli D, Hayman SR, Lust JA, Kapoor P, Lin Y, Go RS, Hwa YL, Kyle RA, **Kumar SK**. Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myeloma. *Am J Hematol*. 2015 Oct; 90(10):888-91. Epub 2015 Sep 01.
14. Alhaj Moustafa M, Rajkumar SV, Dispenzieri A, Gertz MA, Lacy MQ, Buadi FK, Hwa YL, Dingli D, Kapoor P, Hayman SR, Lust JA, Kyle RA, **Kumar SK**. Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapy. *Leukemia*. 2015 Oct; 29(10):2033-8. Epub 2015 May 12
15. Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, Lahuerta JJ, Facon T, Bringhen S, Gay F, Attal M, Passera R, Spencer A, Offidani M, **Kumar S**, Musto P, Lonial S, Petrucci MT, Orłowski RZ, Zamagni E, Morgan G, Dimopoulos MA, Durie BG, Anderson KC, Sonneveld P, San Miguel J, Cavo M, Rajkumar SV, Moreau P. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. *J Clin Oncol*. 2015 Sep 10; 33(26):2863-9. Epub 2015 Aug 03.
16. **Kumar SK**, Krishnan A, LaPlant B, Laumann K, Roy V, Zimmerman T, Gertz MA, Buadi FK, Stockerl Goldstein K, Birgin A, Fiala M, Duarte L, Maharaj M, Levy J, Vij R. Bendamustine, lenalidomide, and dexamethasone (BRD) is highly effective with durable responses in relapsed multiple myeloma. *Am J Hematol*. 2015 Sep 2. [Epub ahead of print]
17. **Kumar SK**, Ma E, Engebretson AE, Buadi FK, Lacy MQ, Dispenzieri A, Duh MS, Lafeuille MH, Lefebvre P, Cheng WY, Dea K, Rembert D, Patt D, Niculescu L, Quick M, Rajkumar SV. Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma. *Leukemia*. 2015 Aug 14.
18. Dispenzieri A, Buadi F, **Kumar SK**, Reeder CB, Sher T, Lacy MQ, Kyle RA, Mikhael JR, Roy V, Leung N, Grogan M, Kapoor P, Lust JA, Dingli D, Go RS, Hwa YL, Hayman SR, Fonseca R, Ailawadhi S, Bergsagel PL, Chanan-Khan A, Rajkumar SV, Russell SJ, Stewart K, Zeldenrust SR, Gertz MA. Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement. *Mayo Clin Proc*. 2015 Aug; 90(8):1054-81.

19. Gonsalves WI, Godby K, **Kumar SK**, Costa LJ. Limiting early mortality: Do's and don'ts in the management of patients with newly diagnosed multiple myeloma. *Am J Hematol*. 2015 Jul 27.
20. Chawla SS, **Kumar SK**, Dispenzieri A, Greenberg AJ, Larson DR, Kyle RA, Lacy MQ, Gertz MA, Rajkumar SV. Clinical course and prognosis of non-secretory multiple myeloma. *Eur J Haematol*. 2015 Jul; 95(1):57-64. Epub 2015 Jan 21
21. Dispenzieri A, Gertz MA, Saenger A, **Kumar SK**, Lacy MQ, Buadi FK, Dingli D, Leung N, Zeldenrust S, Hayman SR, Kapoor P, Grogan M, Hwa L, Russell SJ, Go RS, Rajkumar SV, Kyle RA, Jaffe A. Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T. *Am J Hematol*. 2015 Jun; 90(6):524-8. Epub 2015 Apr 02.
22. Mir MA, Kapoor P, **Kumar S**, Pandey S, Dispenzieri A, Lacy MQ, Dingli D, Hogan W, Buadi F, Hayman S, Gandhi M, Gertz MA. Trends and outcomes in allogeneic hematopoietic stem cell transplant for multiple myeloma at Mayo Clinic. *Clin Lymphoma Myeloma Leuk*. 2015 Jun; 15(6):349-357.e2. Epub 2015 Apr 02.
23. Gertz MA, Terpos E, Dispenzieri A, **Kumar S**, Shah RA, Orlowski R, Kastritis E, Dimopoulos MA, Shah J. Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents. *Leuk Lymphoma*. 2015 Jun; 56(6):1723-6.
24. Bhutani G, Nasr SH, Said SM, Sethi S, Fervenza FC, Morice WG, Kurtin PJ, Buadi FK, Dingli D, Dispenzieri A, Gertz MA, Lacy MQ, Kapoor P, **Kumar S**, Kyle RA, Rajkumar SV, Leung N. Hematologic characteristics of proliferative glomerulonephritides with nonorganized monoclonal immunoglobulin deposits. *Mayo Clin Proc*. 2015 May; 90(5):587-96.
25. Mahindra A, Raval G, Mehta P, Brazauskas R, Zhang MJ, Zhong X, Bird JM, Freytes CO, Hale GA, Herzig R, Holmberg LA, Kamble RT, **Kumar S**, Lazarus HM, Majhail NS, Marks DI, Moreb JS, Olsson R, Saber W, Savani BN, Schiller GJ, Tay J, Vogl DT, Waller EK, Wiernik PH, Wirk B, Lonial S, Krishnan AY, Dispenzieri A, Brandenburg NA, Gale RP, Hari PN. New cancers after autotransplantations for multiple myeloma. *Biol Blood Marrow Transplant*. 2015 Apr; 21(4):738-45. Epub 2014 Dec 31.
26. Palumbo A, Brinchen S, Mateos MV, Larocca A, Facon T, **Kumar SK**, Offidani M, McCarthy P, Evangelista A, Lonial S, Zweegman S, Musto P, Terpos E, Belch A, Hajek R, Ludwig H, Stewart AK, Moreau P, Anderson K, Einsele H, Durie BG, Dimopoulos MA, Landgren O, San Miguel JF, Richardson P, Sonneveld P, Rajkumar SV. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. *Blood*. 2015 Mar 26; 125(13):2068-74. Epub 2015 Jan 27.
27. Kaufman GP, Dispenzieri A, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, Leung N, Dingli D, Lust JA, Lin Y, Kapoor P, Go RS, Zeldenrust SR, Kyle RA, Rajkumar SV, **Kumar SK**. Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis. *Am J Hematol*. 2015 Mar; 90(3):181-6. Epub 2015 Jan 16.
28. **Kumar SK**. Bisphosphonates in multiple myeloma: a fractured consensus. *Leuk Lymphoma*. 2015 Mar; 56(3):553-4. Epub 2014 Nov 05.
29. Vij R, **Kumar S**, Zhang MJ, Zhong X, Huang J, Dispenzieri A, Abidi MH, Bird JM, Freytes CO, Gale RP, Kindwall-Keller TL, Kyle RA, Landsburg DJ, Lazarus HM, Munker R, Roy V, Sharma M, Vogl DT, Wirk B, Hari PN. Impact of pretransplant therapy and depth of disease response before autologous transplantation for multiple myeloma. *Biol Blood Marrow Transplant*. 2015 Feb; 21(2):335-41. Epub 2014 Nov 01.
30. **Kumar SK**, LaPlant B, Chng WJ, Zonder J, Callander N, Fonseca R, Fruth B, Roy V, Erlichman C, Stewart AK, Mayo Phase 2 Consortium. Dinaciclib, a novel CDK inhibitor,

demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma. *Blood*. 2015 Jan 15; 125(3):443-8. Epub 2014 Nov 13.

31. Costa LJ, **Kumar S**, Stowell SA, Dermer SJ. Mobilization and transplantation patterns of autologous hematopoietic stem cells in multiple myeloma and non-Hodgkin lymphoma. *Cancer Control*. 2015 Jan; 22(1):87-94.
32. Greenberg AJ, Philip S, Paner A, Velinova S, Badros A, Catchatourian R, Ketterling R, Kyle RA, **Kumar S**, Vachon CM, Rajkumar SV. Racial differences in primary cytogenetic abnormalities in multiple myeloma: a multi-center study. *Blood Cancer J*. 2015; 5:e271. Epub 2015 Jan 02.
33. Gonsalves WI, Leung N, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Kapoor P, Go RS, Lin Y, Russell SJ, Lust JA, Zeldenrust S, Kyle RA, Gertz MA, **Kumar SK**. Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma. *Blood Cancer J*. 2015; 5:e296. Epub 2015 Mar 20.
34. Warsame R, **Kumar SK**, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, Leung N, Dingli D, Lust JA, Ketterling RP, Lin Y, Russell S, Hwa L, Kapoor P, Go RS, Zeldenrust SR, Kyle RA, Rajkumar SV, Dispenzieri A. Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death. *Blood Cancer J*. 2015; 5:e310. Epub 2015 May 01.
35. **Kumar SK**, LaPlant B, Roy V, Reeder CB, Lacy MQ, Gertz MA, Laumann K, Thompson MA, Witzig TE, Buadi FK, Rivera CE, Mikhael JR, Bergsagel PL, Kapoor P, Hwa L, Fonseca R, Stewart AK, Chanan-Khan A, Rajkumar SV, Dispenzieri A. Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib. *Blood Cancer J*. 2015; 5:e338. Epub 2015 Aug 14.
36. Vu T, Gonsalves W, **Kumar S**, Dispenzieri A, Lacy MQ, Buadi F, Gertz MA, Rajkumar SV. Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma. *Blood Cancer J*. 2015; 5:e363. Epub 2015 Oct 23.
37. Siontis B, **Kumar S**, Dispenzieri A, Drake MT, Lacy MQ, Buadi F, Dingli D, Kapoor P, Gonsalves W, Gertz MA, Rajkumar SV. Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy. *Blood Cancer J*. 2015; 5:e364. Epub 2015 Oct 23.
38. Ziv E, Dean E, Hu D, Martino A, Serie D, Curtin K, Campa D, Aftab B, Bracci P, Buda G, Zhao Y, Caswell-Jin J, Diasio R, Dumontet C, Dudzinski M, Fejerman L, Greenberg A, Huntsman S, Jamroziak K, Jurczynszyn A, **Kumar S**, Atanackovic D, Glenn M, Cannon-Albright LA, Jones B, Lee A, Marques H, Martin T, Martinez-Lopez J, Rajkumar V, Sainz J, Vangsted AJ, Watek M, Wolf J, Slager S, Camp NJ, Canzian F, Vachon C. Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. *Nat Commun*. 2015; 6:7539. Epub 2015 Jul 22.
39. Ziv E, Dean E, Hu D, Martino A, Serie D, Curtin K, Campa D, Aftab B, Bracci P, Buda G, Zhao Y, Caswell-Jin J, Diasio R, Dumontet C, Dudzinski M, Fejerman L, Greenberg A, Huntsman S, Jamroziak K, Jurczynszyn A, **Kumar S**, Atanackovic D, Glenn M, Cannon-Albright LA, Jones B, Lee A, Marques H, Martin T, Martinez-Lopez J, Rajkumar V, Sainz J, Vangsted AJ, Watek M, Wolf J, Slager S, Camp NJ, Canzian F, Vachon C. Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. *Nature Communications*. 2015; 6:7539.
40. **Kumar SK**, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, Stewart AK, Hari P, Roy V, Vescio R, Kaufman JL, Berg D, Liao E, Di Bacco A, Estevam J, Gupta N, Hui AM, Rajkumar V, Richardson PG. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. *Lancet Oncol*. 2014 Dec; 15(13):1503-12. Epub 2014 Nov 14.

41. Kourelis TV, **Kumar SK**, Go RS, Kapoor P, Kyle RA, Buadi FK, Gertz MA, Lacy MQ, Hayman SR, Leung N, Dingli D, Lust JA, Lin Y, Zeldenrust SR, Rajkumar SV, Dispenzieri A. Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias. *Am J Hematol*. 2014 Nov; 89(11):1051-4. Epub 2014 Sep 02.
42. Gonsalves WI, Morice WG, Rajkumar V, Gupta V, Timm MM, Dispenzieri A, Buadi FK, Lacy MQ, Singh PP, Kapoor P, Gertz MA, **Kumar SK**. Quantification of clonal circulating plasma cells in relapsed multiple myeloma. *Br J Haematol*. 2014 Nov; 167(4):500-5. Epub 2014 Aug 12.
43. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, **Kumar S**, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BG, Miguel JF. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. *Lancet Oncol*. 2014 Nov; 15(12):e538-48. Epub 2014 Oct 26.
44. Ramakrishnan V, Kimlinger T, Timm M, Haug J, Rajkumar SV, **Kumar S**. Multiple mechanisms contribute to the synergistic anti-myeloma activity of the pan-histone deacetylase inhibitor LBH589 and the rapalog RAD001. *Leuk Res*. 2014 Nov; 38(11):1358-66. Epub 2014 Sep 28.
45. Kyle RA, Larson DR, Therneau TM, Dispenzieri A, Melton LJ 3rd, Benson JT, **Kumar S**, Rajkumar SV. Clinical course of light-chain smouldering multiple myeloma (idiopathic Bence Jones proteinuria): a retrospective cohort study. *Lancet Haematol*. 2014 Oct 1; 1(1):e28-36.
46. Raje N, Faiman B, Harvey RD, Kurtin SE, Lonial S, **Kumar SK**, Cohen AD, Conde MA, Giralt SA, Recine MS, Tombler ER, Stadtmauer E, Jagannath S, Anderson KC, Managing Myeloma Continuing Education Initiative Advisory Group. Identifying professional education gaps and barriers in multiple myeloma patient care: findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee. *Clin Lymphoma Myeloma Leuk*. 2014 Oct; 14(5):356-69. Epub 2014 Jun 12
47. Pandya C, Hashmi S, Khera N, Gertz MA, Dispenzieri A, Hogan W, Siddiqui M, Noyes K, **Kumar SK**. Cost-effectiveness analysis of early vs. late autologous stem cell transplantation in multiple myeloma. *Clin Transplant*. 2014 Oct; 28(10):1084-91.
48. Gonsalves WI, Rajkumar SV, Gupta V, Morice WG, Timm MM, Singh PP, Dispenzieri A, Buadi FK, Lacy MQ, Kapoor P, Gertz MA, **Kumar SK**. Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma. *Leukemia*. 2014 Oct; 28(10):2060-5. Epub 2014 Mar 12.
49. Mughal TI, Girmius S, Rosen ST, **Kumar S**, Wiestner A, Abdel-Wahab O, Kiladjian JJ, Wilson WH, Van Etten RA. Emerging therapeutic paradigms to target the dysregulated janus kinase/signal transducer and activator of transcription pathway in hematological malignancies. *Leuk Lymphoma*. 2014 Sep; 55(9):1968-79.
50. **Kumar SK**, Bensinger WI, Zimmerman TM, Reeder CB, Berenson JR, Berg D, Hui AM, Gupta N, Di Bacco A, Yu J, Shou Y, Niesvizky R. Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. *Blood*. 2014 Aug 14; 124(7):1047-55. Epub 2014 Jun 05.
51. Gonsalves WI, Rajkumar SV, Go RS, Dispenzieri A, Gupta V, Singh PP, Buadi FK, Lacy MQ, Kapoor P, Dingli D, Lust JA, Zeldenrust SR, Hayman SR, Kyle RA, Gertz MA, **Kumar SK**. Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. *Blood*. 2014 Aug 7; 124(6):907-12. Epub 2014 Jun 23.
52. Glavey SV, Gertz MA, Dispenzieri A, **Kumar S**, Buadi F, Lacy M, Hayman SR, Kapoor P, Dingli D, McCurdy A, Hogan WJ, Gastineau DA, Leung N. Long-term outcome of patients

with multiple myeloma-related advanced renal failure following auto-SCT. Bone Marrow Transplant. 2014 Jul; 49(7):996.

53. Ramakrishnan V, Painuly U, Kimlinger T, Haug J, Rajkumar SV, **Kumar S**. Inhibitor of apoptosis proteins as therapeutic targets in multiple myeloma. Leukemia. 2014 Jul; 28(7):1519-28. Epub 2014 Jan 09.
54. Landgren O, Graubard BI, Katzmann JA, Kyle RA, Ahmadizadeh I, Clark R, **Kumar SK**, Dispenzieri A, Greenberg AJ, Therneau TM, Melton LJ 3rd, Caporaso N, Korde N, Roschewski M, Costello R, McQuillan GM, Rajkumar SV. Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey. Leukemia. 2014 Jul; 28(7):1537-42. Epub 2014 Jan 20.
55. Warsame R, Bang SM, **Kumar SK**, Gertz MA, Lacy MQ, Buadi F, Dingli D, Hayman SR, Kapoor P, Kyle RA, Leung N, Lust JA, Russell SJ, Witzig TE, Zeldenrust SR, Rajkumar SV, Dispenzieri A. Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplant. Eur J Haematol. 2014 Jun; 92(6):485-90. Epub 2014 Mar 2.
56. **Kumar SK**, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, Kapoor P, Dingli D, Hayman SR, Leung N, Lust J, McCurdy A, Russell SJ, Zeldenrust SR, Kyle RA, Rajkumar SV. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014 May; 28(5):1122-8. Epub 2013 Oct 25.
57. Parikh SA, Kapoor P, Letendre L, **Kumar S**, Wolanskyj AP. Prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosis. Mayo Clin Proc. 2014 Apr; 89(4):484-92. Epub 2014 Feb 26.
58. Kourelis TV, **Kumar SK**, Srivastava G, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, Zeldenrust SR, Leung N, Kyle RA, Russell SJ, Dingli D, Lust JA, Lin Y, Kapoor P, Go R, Rajkumar SV, Dispenzieri A. Long-term disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy. Am J Hematol. 2014 Mar; 89(3):302-5. Epub 2014 Feb 18.
59. Dispenzieri A, Gertz MA, **Kumar SK**, Lacy MQ, Kyle RA, Saenger AK, Grogan M, Zeldenrust SR, Hayman SR, Buadi F, Greipp PR, Leung N, Russell SR, Dingli D, Lust JA, Rajkumar SV, Jaffe AS. High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis. Heart. 2014 Mar; 100(5):383-8. Epub 2014 Jan 08.
60. Palumbo A, Bringhen S, **Kumar SK**, Lupparelli G, Usmani S, Waage A, Larocca A, van der Holt B, Musto P, Offidani M, Petrucci MT, Evangelista A, Zweegman S, Nooka AK, Spencer A, Dimopoulos MA, Hajek R, Cavo M, Richardson P, Lonial S, Ciccone G, Boccadoro M, Anderson K, Barlogie B, Sonneveld P, McCarthy PL. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol. 2014 Mar; 15(3):333-42. Epub 2014 Feb 11.
61. Ocio EM, Richardson PG, Rajkumar SV, Palumbo A, Mateos MV, Orlowski R, **Kumar S**, Usmani S, Roodman D, Niesvizky R, Einsele H, Anderson KC, Dimopoulos MA, Avet-Loiseau H, Mellqvist UH, Turesson I, Merlini G, Schots R, McCarthy P, Bergsagel L, Chim CS, Lahuerta JJ, Shah J, Reiman A, Mikhael J, Zweegman S, Lonial S, Comenzo R, Chng WJ, Moreau P, Sonneveld P, Ludwig H, Durie BG, Miguel JF. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia. 2014 Mar; 28(3):525-42. Epub 2013 Nov 20.
62. Costa LJ, Nista EJ, Buadi FK, Lacy MQ, Dispenzieri A, Kramer CP, Edwards KH, Kang Y, Gertz MA, Stuart RK, **Kumar S**. Prediction of poor mobilization of autologous CD34+ cells with growth factor in multiple myeloma patients: implications for risk-stratification.

Biol Blood Marrow Transplant. 2014 Feb; 20(2):222-8. Epub 2013 Nov 6

63. **Kumar SK**, Mikhael J, Laplant B, Lacy MQ, Buadi FK, Dingli D, Gertz MA, Laumann K, Miceli T, Mahlman M, Bergsagel LP, Hayman SR, Reeder C, Stewart AK, Dispenzieri A, Gastineau DA, Winters JL. Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy. *Bone Marrow Transplant*. 2014 Feb; 49(2):201-5. Epub 2013 Nov 04.
64. Paulus A, Chitta K, Akhtar S, Personett D, Miller KC, Thompson KJ, Carr J, **Kumar S**, Roy V, Ansell SM, Mikhael JR, Dispenzieri A, Reeder CB, Rivera CE, Foran J, Chanan-Khan A. AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenstrom macroglobulinaemia. *Br J Haematol*. 2014 Feb; 164(3):352-65. Epub 2013 Nov 17.
65. **Kumar S**. Maintenance therapy in multiple myeloma. *Clin Adv Hematol Oncol*. 2014 Feb; 12(2):133-4.
66. Rosinol L, **Kumar S**, Moreau P, Cavo M. Initial treatment of transplant-eligible patients in multiple myeloma. *Expert Rev Hematol*. 2014 Feb; 7(1):43-53. Epub 2014 Jan 07.
67. Greenberg AJ, Rajkumar SV, Therneau TM, Singh PP, Dispenzieri A, **Kumar SK**. Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma. *Leukemia*. 2014 Feb; 28(2):398-403. Epub 2013 Sep 05.
68. Farr JN, Zhang W, **Kumar SK**, Jacques RM, Ng AC, McCready LK, Rajkumar SV, Drake MT. Altered cortical microarchitecture in patients with monoclonal gammopathy of undetermined significance. *Blood*. 2014 Jan 30; 123(5):647-9. Epub 2013 Nov 13.
69. Schuster SR, Kortuem KM, Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Ahmann G, **Kumar S**, Rajkumar SV, Mikhael J, Laplant B, Champion MD, Laumann K, Barlogie B, Fonseca R, Bergsagel PL, Lacy M, Stewart AK. The clinical significance of cereblon expression in multiple myeloma. *Leuk Res*. 2014 Jan; 38(1):23-8. Epub 2013 Sep 05.
70. Glavey SV, Gertz MA, Dispenzieri A, **Kumar S**, Buadi F, Lacy M, Hayman SR, Kapoor P, Dingli D, McCurdy A, Hogan WJ, Gastineau DA, Leung N. Erratum: Long-term outcome of patients with multiple myeloma-related advanced renal failure following auto-SCT (Bone Marrow Transplantation (2014) 49 (996) DOI:10.1038/bmt.2014.24). *Bone Marrow Transplant*. 2014; 49(7):996.
71. **Kumar S**. Post-transplant therapy in multiple myeloma: A hung jury? *The Lancet Haematology*. 2014; 1(3):e90-1.
72. Kapoor P, **Kumar SK**, Dispenzieri A, Lacy MQ, Buadi F, Dingli D, Russell SJ, Hayman SR, Witzig TE, Lust JA, Leung N, Lin Y, Zeldenrust SR, McCurdy A, Greipp PR, Kyle RA, Rajkumar SV, Gertz MA. Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. *J Clin Oncol*. 2013 Dec 20; 31(36):4529-35. Epub 2013 Nov 18.
73. Dispenzieri A, Stewart AK, Chanan-Khan A, Rajkumar SV, Kyle RA, Fonseca R, Kapoor P, Bergsagel PL, McCurdy A, Gertz MA, Lacy MQ, Lust JA, Russell SJ, Zeldenrust SR, Reeder C, Roy V, Buadi F, Dingli D, Hayman SR, Leung N, Lin Y, Mikhael J, **Kumar SK**. Smoldering multiple myeloma requiring treatment: time for a new definition? *Blood*. 2013 Dec 19; 122(26):4172-81. Epub 2013 Oct 21.
74. Burnette BL, Dispenzieri A, **Kumar S**, Harris AM, Sloan JA, Tilburt JC, Kyle RA, Rajkumar SV. Treatment trade-offs in myeloma: A survey of consecutive patients about contemporary maintenance strategies. *Cancer*. 2013 Dec 15; 119(24):4308-15. Epub 2013 Sep 19.

75. Kourelis TV, **Kumar SK**, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, Zeldenrust S, Leung N, Kyle RA, Russell S, Dingli D, Lust JA, Lin Y, Kapoor P, Rajkumar SV, McCurdy A, Dispenzieri A. Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. *J Clin Oncol*. 2013 Dec 1; 31(34):4319-24. Epub 2013 Oct 21.
76. Greenberg AJ, Walters DK, **Kumar SK**, Vincent Rajkumar S, Jelinek DF. Responsiveness of cytogenetically discrete human myeloma cell lines to lenalidomide: lack of correlation with cereblon and interferon regulatory factor 4 expression levels. *Eur J Haematol*. 2013 Dec; 91(6):504-13. Epub 2013 Sep 17.
77. Costa LJ, Zhang MJ, Zhong X, Dispenzieri A, Lonial S, Krishnan A, Freytes C, Vesole D, Gale RP, Anderson K, Wirk B, Savani BN, Waller EK, Schouten H, Lazarus H, Meehan K, Sharma M, Kamble R, Vij R, **Kumar S**, Nishihori T, Kindwall-Keller T, Saber W, Hari PN. Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma. *Biol Blood Marrow Transplant*. 2013 Nov; 19(11):1615-24. Epub 2013 Aug 11.
78. Glavey SV, Gertz MA, Dispenzieri A, **Kumar S**, Buadi F, Lacy M, Hayman SR, Dingli D, McCurdy A, Hogan WJ, Gastineau DA, Leung N. Long-term outcome of patients with multiple myeloma-related advanced renal failure following auto-SCT. *Bone Marrow Transplant*. 2013 Nov; 48(12):1543-7. Epub 2013 Aug 05.
79. Thyagarajan B, Arora M, Guan W, Barcelo H, Jackson S, **Kumar S**, Gertz M. Genetic variants in DNA repair pathways are not associated with disease progression among multiple myeloma patients. *Leuk Res*. 2013 Nov; 37(11):1527-31. Epub 2013 Oct 12.
80. Dispenzieri A, Seenithamby K, Lacy MQ, **Kumar SK**, Buadi FK, Hayman SR, Dingli D, Litzow MR, Gastineau DA, Inwards DJ, Micallef IN, Ansell SM, Johnston PB, Porrata LF, Patnaik MM, Hogan WJ, Gertz MA. Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center. *Bone Marrow Transplant*. 2013 Oct; 48(10):1302-7. Epub 2013 Apr 22.
81. **Kumar SK**, Jett J, Marks R, Richardson R, Quevedo F, Moynihan T, Croghan G, Markovic SN, Bible KC, Qin R, Tan A, Molina J, Kaufmann SH, Erlichman C, Adjei AA. Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies. *Invest New Drugs*. 2013 Oct; 31(5):1201-6. Epub 2013 Jul 26
82. Srivastava G, Rana V, Lacy MQ, Buadi FK, Hayman SR, Dispenzieri A, Gertz MA, Dingli D, Zeldenrust S, Russell S, McCurdy A, Kapoor P, Kyle R, Rajkumar SV, **Kumar S**. Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma. *Leukemia*. 2013 Oct; 27(10):2062-6. Epub 2013 May 07.
83. Gonsalves WI, Gertz MA, Dispenzieri A, Lacy MQ, Lin Y, Singh PP, Gupta V, Hayman SR, Buadi FK, Dingli D, Kapoor P, McCurdy AR, **Kumar SK**. Implications of continued response after autologous stem cell transplantation for multiple myeloma. *Blood*. 2013 Sep 5; 122(10):1746-9. Epub 2013 Jul 17.
84. Galanis E, Anderson SK, Lafky JM, Uhm JH, Giannini C, **Kumar SK**, Kimlinger TK, Northfelt DW, Flynn PJ, Jaecle KA, Kaufmann TJ, Buckner JC. Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial. *Clin Cancer Res*. 2013 Sep 1; 19(17):4816-23. Epub 2013 Jul 05.
85. Keyzner A, D'Souza A, Lacy M, Gertz M, Hayman S, Buadi F, **Kumar S**, Dingli D, Engebretson A, Tong C, Dispenzieri A. Low levels of interleukin-1 receptor antagonist (IL-1RA) predict engraftment syndrome after autologous stem cell transplantation in POEMS syndrome and other plasma cell neoplasms. *Biol Blood Marrow Transplant*. 2013 Sep; 19(9):1395-8. Epub 2013 Jun 20.

86. Greenberg AJ, Cousin M, **Kumar S**, Ketterling RP, Knudson RA, Larson D, Colby C, Scott C, Vachon CM, Rajkumar SV. Differences in the distribution of cytogenetic subtypes between multiple myeloma patients with and without a family history of monoclonal gammopathy and multiple myeloma. *Eur J Haematol*. 2013 Sep; 91(3):193-5. Epub 2013 Jul 22.
87. Singla A, Hogan WJ, Ansell SM, Buadi FK, Dingli D, Dispenzieri A, Gastineau DA, Gertz MA, Hayman SR, Inwards DJ, Johnston PB, Lacy MQ, Litzow MR, Micallef IN, Porrata LF, **Kumar SK**. Incidence of supraventricular arrhythmias during autologous peripheral blood stem cell transplantation. *Biol Blood Marrow Transplant*. 2013 Aug; 19(8):1233-7. Epub 2013 Jun 06.
88. Rajkumar SV, Gupta V, Fonseca R, Dispenzieri A, Gonsalves WI, Larson D, Ketterling RP, Lust JA, Kyle RA, **Kumar SK**. Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. *Leukemia*. 2013 Aug; 27(8):1738-44. Epub 2013 Mar 21.
89. Hegerova LT, Swiecicki PL, **Kumar SK**. 35-year-old man with Fever and abdominal pain. *Mayo Clin Proc*. 2013 Aug; 88(8):866-70.
90. Humeniuk MS, Gertz MA, Lacy MQ, Kyle RA, Witzig TE, **Kumar SK**, Kapoor P, Lust JA, Hayman SR, Buadi FK, Rajkumar SV, Zeldenrust SR, Russell SJ, Dingli D, Lin Y, Leung N, Dispenzieri A. Outcomes of patients with POEMS syndrome treated initially with radiation. *Blood*. 2013 Jul 4; 122(1):68-73. Epub 2013 May 22.
91. Leung N, Glavey SV, **Kumar S**, Dispenzieri A, Buadi FK, Dingli D, Lacy MQ, Hayman SR, Lust JA, Russell SJ, Zeldenrust SR, Rajkumar SV, Gertz MA. A detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision? *Haematologica*. 2013 Jun; 98(6):988-92.
92. Kourelis TV, Gertz M, Zent C, Lacy M, Kyle R, Kapoor P, Zeldenrust S, Buadi F, Witzig T, Hayman S, Lust J, Russell S, Lin Y, Rajkumar VS, **Kumar S**, Leung N, Dingli D, Dispenzieri A. Systemic amyloidosis associated with chronic lymphocytic leukemia/small lymphocytic lymphoma. *Am J Hematol*. 2013 May; 88(5):375-8. Epub 2013 Mar 19.
93. Michaelis LC, Saad A, Zhong X, Le-Rademacher J, Freytes CO, Marks DI, Lazarus HM, Bird JM, Holmberg L, Kamble RT, **Kumar S**, Lill M, Meehan KR, Saber W, Schriber J, Tay J, Vogl DT, Wirk B, Savani BN, Gale RP, Vesole DH, Schiller GJ, Abidi M, Anderson KC, Nishihori T, Kalaycio ME, Vose JM, Moreb JS, Drobyski W, Munker R, Roy V, Ghobadi A, Holland HK, Nath R, To LB, Maiolino A, Kassim AA, Giralt SA, Landau H, Schouten HC, Maziarz RT, Michael J, Kindwall-Keller T, Stiff PJ, Gibson J, Lonial S, Krishnan A, Dispenzieri A, Hari P, Plasma Cell Disorders Working Committee of the Center for International Blood and Marrow Transplant Research. Salvage second hematopoietic cell transplantation in myeloma. *Biol Blood Marrow Transplant*. 2013 May; 19(5):760-6. Epub 2013 Jan 5
94. Gertz MA, Lacy MQ, Dispenzieri A, **Kumar SK**, Dingli D, Leung N, Hogan WJ, Buadi FK, Hayman SR. Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis. *Bone Marrow Transplant*. 2013 Apr; 48(4):557-61. Epub 2012 Sep 10.
95. Gonsalves WI, Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK, Dingli D, Hogan WJ, **Kumar SK**. Second auto-SCT for treatment of relapsed multiple myeloma. *Bone Marrow Transplant*. 2013 Apr; 48(4):568-73. Epub 2012 Sep 24.
96. Kyle RA, Therneau TM, Dispenzieri A, **Kumar S**, Benson JT, Larson DR, Melton LJ 3rd, Rajkumar SV. Immunoglobulin m monoclonal gammopathy of undetermined significance and smoldering Waldenstrom macroglobulinemia. *Clin Lymphoma Myeloma Leuk*. 2013 Apr; 13(2):184-6. Epub 2013 Mar 13.
97. Fernandez de Larrea C, Kyle RA, Durie BG, Ludwig H, Usmani S, Vesole DH, Hajek R,

- San Miguel JF, Sezer O, Sonneveld P, **Kumar SK**, Mahindra A, Comenzo R, Palumbo A, Mazumber A, Anderson KC, Richardson PG, Badros AZ, Caers J, Cavo M, LeLeu X, Dimopoulos MA, Chim CS, Schots R, Noeul A, Fantl D, Mellqvist UH, Landgren O, Chanan-Khan A, Moreau P, Fonseca R, Merlini G, Lahuerta JJ, Blade J, Orłowski RZ, Shah JJ, International Myeloma Working Group. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. *Leukemia*. 2013 Apr; 27(4):780-91. Epub 2012 Nov 21
98. Larsen JT, **Kumar SK**, Dispenzieri A, Kyle RA, Katzmann JA, Rajkumar SV. Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. *Leukemia*. 2013 Apr; 27(4):941-6. Epub 2012 Oct 16.
99. Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR, Dispenzieri A, Fonseca R, Sher T, Kyle RA, Lin Y, Russell SJ, **Kumar S**, Bergsagel PL, Zeldenzust SR, Leung N, Drake MT, Kapoor P, Ansell SM, Witzig TE, Lust JA, Dalton RJ, Gertz MA, Stewart AK, Rajkumar SV, Chanan-Khan A, Lacy MQ, Mayo Clinic. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. *Mayo Clin Proc*. 2013 Apr; 88(4):360-76.
100. **Kumar SK**. Digging deeper with allogeneic transplantation in multiple myeloma. *Biol Blood Marrow Transplant*. 2013 Mar; 19(3):335-6. Epub 2013 Jan 02.
101. Greenberg AJ, Lee AM, Serie DJ, McDonnell SK, Cerhan JR, Liebow M, Larson DR, Colby CL, Norman AD, Kyle RA, **Kumar S**, Rajkumar SV, Diasio RB, Slager SL, Vachon CM. Single-nucleotide polymorphism rs1052501 associated with monoclonal gammopathy of undetermined significance and multiple myeloma. *Leukemia*. 2013 Feb; 27(2):515-6. Epub 2012 Aug 16
102. Micallef IN, Sinha S, Gastineau DA, Wolf R, Inwards DJ, Gertz MA, Hayman SR, Hogan WJ, Johnston PB, Lacy MQ, Ansell SM, Buadi F, Dingli D, Dispenzieri A, Litzow MR, Porrata LF, Winters JL, **Kumar S**. Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization. *Biol Blood Marrow Transplant*. 2013 Jan; 19(1):87-93. Epub 2012 Aug 23.
103. Witzig TE, Laumann KM, Lacy MQ, Hayman SR, Dispenzieri A, **Kumar S**, Reeder CB, Roy V, Lust JA, Gertz MA, Greipp PR, Hassoun H, Mandrekar SJ, Rajkumar SV. A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma. *Leukemia*. 2013 Jan; 27(1):220-5. Epub 2012 Aug 20.
104. Bianchi G, Sacco A, **Kumar S**, Rossi G, Ghobrial I, Roccaro A. Candidate genes of Waldenström's macroglobulinemia: Current evidence and research. *Application of Clinical Genetics*. 2013; 6:32-42.
105. Chanan-Khan AA, Swaika A, Paulus A, **Kumar SK**, Mikhael JR, Rajkumar SV, Dispenzieri A, Lacy MQ. Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma. *Blood Cancer J*. 2013; 3:e143. Epub 2013 Sep 06.
106. Painuly U, **Kumar S**. Efficacy of bortezomib as first-line treatment for patients with multiple myeloma. *Clin Med Insights Oncol*. 2013; 7:53-73. Epub 2013 Feb 28.
107. Palladini G, Dispenzieri A, Gertz MA, **Kumar S**, Wechalekar A, Hawkins PN, Schonland S, Hegenbart U, Comenzo R, Kastiris E, Dimopoulos MA, Jaccard A, Klersy C, Merlini G. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. *J Clin Oncol*. 2012 Dec 20; 30(36):4541-9. Epub 2012 Oct 22.
108. Cordes S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Dingli D, **Kumar SK**, Hogan WJ, Gertz MA. Ten-year survival after autologous stem cell transplantation for

immunoglobulin light chain amyloidosis. *Cancer*. 2012 Dec 15; 118(24):6105-9. Epub 2012 Jun 15.

109. Leung N, Gertz M, Kyle RA, Fervenza FC, Irazabal MV, Eirin A, **Kumar S**, Cha SS, Rajkumar SV, Lacy MQ, Zeldenrust SR, Buadi FK, Hayman SR, Nasr SH, Sethi S, Ramirez-Alvarado M, Witzig TE, Herrmann SM, Dispenzieri A. Urinary albumin excretion patterns of patients with cast nephropathy and other monoclonal gammopathy-related kidney diseases. *Clin J Am Soc Nephrol*. 2012 Dec; 7(12):1964-8. Epub 2012 Sep 27.
110. Therneau TM, Kyle RA, Melton LJ, Larson DR, Benson JT, Colby CL, Dispenzieri A, **Kumar S**, Katzmman JA, Cerhan JR, Rajkumar SV. Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition. *Mayo Clin Proc*. 2012 Nov; 87(11):1071-9. Epub 2012 Aug 07.
111. Bleeker JS, Gertz MA, Pellikka PA, Larson DR, Buadi F, Dingli D, Dispenzieri A, Hayman SR, Hogan W, **Kumar S**, Rajkumar SV, Lacy MQ. Evaluation of pretransplant factors predicting cardiac dysfunction following high-dose melphalan conditioning and autologous peripheral blood stem cell transplantation. *Eur J Haematol*. 2012 Sep; 89(3):228-35. Epub 2012 Jul 13.
112. Keats JJ, Chesi M, Egan JB, Garbitt VM, Palmer SE, Braggio E, Van Wier, Blackburn PR, Baker AS, Dispenzieri A, **Kumar S**, Rajkumar SV, Carpten JD, Barrett M, Fonseca R, Stewart AK, Bergsagel PL. Clonal competition with alternating dominance in multiple myeloma. *Blood*. 2012 Aug 2; 120(5):1067-76. Epub 2012 Apr 12
113. D'Souza A, Lacy M, Gertz M, **Kumar S**, Buadi F, Hayman S, Dingli D, Zeldenrust S, Kyle R, Ansell S, Inwards D, Johnston P, Micallef I, Porrata L, Litzow M, Gastineau D, Hogan W, Dispenzieri A. Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experience. *Blood*. 2012 Jul 5; 120(1):56-62. Epub 2012 May 18.
114. Warsame R, Gertz MA, Lacy MQ, Kyle RA, Buadi F, Dingli D, Greipp PR, Hayman SR, **Kumar SK**, Lust JA, Russell SJ, Witzig TE, Mikhael J, Leung N, Zeldenrust SR, Rajkumar SV, Dispenzieri A. Trends and outcomes of modern staging of solitary plasmacytoma of bone. *Am J Hematol*. 2012 Jul; 87(7):647-51. Epub 2012 May 02.
115. Dispenzieri A, Buadi F, Laumann K, LaPlant B, Hayman SR, **Kumar SK**, Dingli D, Zeldenrust SR, Mikhael JR, Hall R, Rajkumar SV, Reeder C, Fonseca R, Bergsagel PL, Stewart AK, Roy V, Witzig TE, Lust JA, Russell SJ, Gertz MA, Lacy MQ. Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. *Blood*. 2012 Jun 7; 119(23):5397-404. Epub 2012 Apr 04.
116. Dispenzieri A, Katzmman JA, Kyle RA, Larson DR, Therneau TM, Colby CL, Clark RJ, Mead GP, **Kumar S**, Melton LJ, Rajkumar SV. Use of nonclonal serum immunoglobulin free light chains to predict overall survival in the general population. *Mayo Clin Proc*. 2012 Jun; 87(6):517-23.
117. **Kumar SK**, Hayman SR, Buadi FK, Roy V, Lacy MQ, Gertz MA, Allred J, Laumann KM, Bergsagel LP, Dingli D, Mikhael JR, Reeder CB, Stewart AK, Zeldenrust SR, Greipp PR, Lust JA, Fonseca R, Russell SJ, Rajkumar SV, Dispenzieri A. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. *Blood*. 2012 May 24; 119(21):4860-7. Epub 2012 Apr 13.
118. **Kumar S**, Flinn I, Richardson PG, Hari P, Callander N, Noga SJ, Stewart AK, Turturro F, Rifkin R, Wolf J, Estevam J, Mulligan G, Shi H, Webb IJ, Rajkumar SV. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. *Blood*. 2012 May 10; 119(19):4375-82. Epub 2012 Mar 15.
119. Kyle RA, Benson JT, Larson DR, Therneau TM, Dispenzieri A, **Kumar S**, Melton LJ, Rajkumar SV. Progression in smoldering Waldenström macroglobulinemia: long-term

results. *Blood*. 2012 May 10; 119(19):4462-6. Epub 2012 Mar 26.

120. Greenberg AJ, Rajkumar SV, Larson DR, Dispenziera A, Therneau TM, Colby CL, Phelps TK, **Kumar SK**, Katzmann JA, Kyle RA, Slager SL, Vachon CM. Increased prevalence of light chain monoclonal gammopathy of undetermined significance (LC-MGUS) in first-degree relatives of individuals with multiple myeloma. *Br J Haematol*. 2012 May; 157(4):472-5.
121. Mahindra A, Kalaycio ME, Vela-Ojeda J, Vesole DH, Zhang MJ, Li P, Berenson JR, Bird JM, Dispenziera A, Gajewski JL, Gale RP, Holmberg L, **Kumar S**, Kyle RA, Lazarus HM, Lonial S, Mikhael J, Milone GA, Munker R, Nath R, Saccaro S, To LB, Vogl DT, Wirk B, Hari P. Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research. *Leukemia*. 2012 May; 26(5):1091-7. Epub 2011 Nov 01.
122. **Kumar S**, Dispenziera A, Lacy MQ, Hayman SR, Buadi FK, Colby C, Laumann K, Zeldenrust SR, Leung N, Dingli D, Greipp PR, Lust JA, Russell SJ, Kyle RA, Rajkumar SV, Gertz MA. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. *J Clin Oncol*. 2012 Mar 20; 30(9):989-95. Epub 2012 Feb 13.
123. **Kumar SK**, Lacy MQ, Dispenziera A, Buadi FK, Hayman SR, Dingli D, Gay F, Sinha S, Leung N, Hogan W, Rajkumar SV, Gertz MA. Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma. *Cancer*. 2012 Mar 15; 118(6):1585-92. Epub 2011 Aug 25.
124. **Kumar S**, Fonseca R, Ketterling RP, Dispenziera A, Lacy MQ, Gertz MA, Hayman SR, Buadi FK, Dingli D, Knudson RA, Greenberg A, Russell SJ, Zeldenrust SR, Lust JA, Kyle RA, Bergsagel L, Rajkumar SV. Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. *Blood*. 2012 Mar 1; 119(9):2100-5. Epub 2012 Jan 10.
125. Ramakrishnan V, Timm M, Haug JL, Kimlinger TK, Halling T, Wellik LE, Witzig TE, Rajkumar SV, Adjei AA, **Kumar S**. Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin. *Am J Hematol*. 2012 Mar; 87(3):277-83. Epub 2011 Dec 21.
126. **Kumar S**. Risk of early death in multiple myeloma. *Clin Adv Hematol Oncol*. 2012 Mar; 10(3):172-4.
127. Eirin A, Irazabal MV, Gertz MA, Dispenziera A, Lacy MQ, **Kumar S**, Sethi S, Nasr SH, Cornell LD, Fidler ME, Fervenza FC, Leung N. Clinical features of patients with immunoglobulin light chain amyloidosis (AL) with vascular-limited deposition in the kidney. *Nephrol Dial Transplant*. 2012 Mar; 27(3):1097-101. Epub 2011 Nov 07.
128. Bianchi G, **Kumar S**, Ghobrial IM, Rocco AM. Cell Trafficking in Multiple Myeloma. *Open J Hematol*. 2012 Feb 21; 3(Suppl 1).
129. Madan S, **Kumar SK**, Dispenziera A, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Rajkumar SV, Hogan WJ, Leung N, Grogan M, Gertz MA. High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement. *Blood*. 2012 Feb 2; 119(5):1117-22. Epub 2011 Dec 06.
130. Khan ML, Reeder CB, **Kumar SK**, Lacy MQ, Reece DE, Dispenziera A, Gertz MA, Greipp P, Hayman S, Zeldenhurst S, Dingli D, Lust J, Russell S, Laumann KM, Mikhael JR, Leif Bergsagel, Fonseca R, Vincent Rajkumar, Keith Stewart. A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma. *Br J Haematol*. 2012 Feb; 156(3):326-33. Epub 2011 Nov 23.

131. Ramakrishnan V, Ansell S, Haug J, Grote D, Kimlinger T, Stenson M, Timm M, Wellik L, Halling T, Rajkumar SV, **Kumar S**. MRK003, a gamma-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphoma. *Leukemia*. 2012 Feb; 26(2):340-8. Epub 2011 Aug 09.
132. Gertz MA, Buadi FK, Hayman SR, Dingli D, Dispenzieri A, Greipp PR, **Kumar SK**, Lacy MQ, Lust JA, Leung N, Rajkumar SV, Russell SJ, Zeldenrust SR, Mikhael JR, Roy V, Kyle RA. Immunoglobulin D amyloidosis: a distinct entity. *Blood*. 2012 Jan 5; 119(1):44-8. Epub 2011 Nov 07.
133. Ozsan GH, Micallef IN, Dispenzieri A, **Kumar S**, Lacy MQ, Dingli D, Hayman SR, Buadi FK, Wolf RC, Gastineau DA, Hogan WJ, Gertz MA. Hematopoietic recovery kinetics predicts for poor CD34+ cell mobilization after cyclophosphamide chemotherapy in multiple myeloma. *Am J Hematol*. 2012 Jan; 87(1):1-4. Epub 2011 Sep 29.
134. Irazabal MV, Eirin A, Gertz MA, Dispenzieri A, **Kumar S**, Buadi FK, Lacy MQ, Hayman SR, Dingli D, Hogan WJ, Gastineau DA, Glavey SV, Amer H, Leung N. Acute kidney injury during leukocyte engraftment after autologous stem cell transplantation in patients with light-chain amyloidosis. *Am J Hematol*. 2012 Jan; 87(1):51-4. Epub 2011 Nov 11.
135. **Kumar SK**, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, LeLeu X, Hulin C, Klein SK, Sonneveld P, Siegel D, Blade J, Goldschmidt H, Jagannath S, Miguel JS, Orlowski R, Palumbo A, Sezer O, Rajkumar SV, Durie BG, International Myeloma Working Group. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. *Leukemia*. 2012 Jan; 26(1):149-57. Epub 2011 Jul 29.
136. Painuly U, **Kumar S**. Efficacy of bortezomib as first-line treatment for patients with multiple myeloma. *Clinical Medicine Insights: Oncology*. 2012; 7:53-73.
137. Ramakrishnan V, Kimlinger T, Haug J, Painuly U, Wellik L, Halling T, Rajkumar SV, **Kumar S**. Anti-myeloma activity of Akt inhibition is linked to the activation status of PI3K/Akt and MEK/ERK pathway. *PLoS One*. 2012; 7(11):e50005. Epub 2012 Nov 21.
138. Ng AC, Khosla S, Charatcharoenwithaya N, **Kumar SK**, Achenbach SJ, Holets MF, McCready LK, Melton LJ 3rd, Kyle RA, Rajkumar SV, Drake MT. Bone microstructural changes revealed by high-resolution peripheral quantitative computed tomography imaging and elevated DKK1 and MIP-1alpha levels in patients with MGUS. *Blood*. 2011 Dec 15; 118(25):6529-34. Epub 2011 Oct 31.
139. Kapoor P, Thenappan T, Singh E, **Kumar S**, Greipp PR. Cardiac amyloidosis: a practical approach to diagnosis and management. *Am J Med*. 2011 Nov; 124(11):1006-15.
140. Jacobus SJ, **Kumar S**, Uno H, Van Wier, Ahmann GJ, Henderson KJ, Callander NS, Williams ME, Siegel DS, Greipp PR, Rajkumar SV, Fonseca R. Impact of high-risk classification by FISH: an eastern cooperative oncology group (ECOG) study E4A03. *Br J Haematol*. 2011 Nov; 155(3):340-8. Epub 2011 Sep 09.
141. D'Souza A, Hayman SR, Buadi F, Mauermann M, Lacy MQ, Gertz MA, Kyle RA, **Kumar S**, Greipp PR, Lust JA, Russell SJ, Zeldenrust S, Dingli D, Witzig TE, Rajkumar SV, Dispenzieri A. The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome. *Blood*. 2011 Oct 27; 118(17):4663-5. Epub 2011 Aug 31.
142. **Kumar SK**, Uno H, Jacobus SJ, Van Wier SA, Ahmann GJ, Henderson KJ, Callander NS, Haug JL, Siegel DS, Greipp PR, Fonseca R, Rajkumar SV. Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone. *Blood*. 2011 Oct 20; 118(16):4359-62. Epub 2011 Aug 22.

143. Lacy MQ, Allred JB, Gertz MA, Hayman SR, Short KD, Buadi F, Dispenzieri A, **Kumar S**, Greipp PR, Lust JA, Russell SJ, Dingli D, Zeldenrust S, Fonseca R, Bergsagel PL, Roy V, Stewart AK, Laumann K, Mandrekar SJ, Reeder C, Rajkumar SV, Mikhael JR. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. *Blood*. 2011 Sep 15; 118(11):2970-5. Epub 2011 Jun 20.
144. Wadhera RK, Kyle RA, Larson DR, Dispenzieri A, **Kumar S**, Lazarus HM, Rajkumar SV. Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma. *Blood*. 2011 Sep 15; 118(11):2985-7. Epub 2011 Jul 15.
145. **Kumar SK**. Myeloma ASH 2010 highlights. *Am J Hematol*. 2011 Sep; 86(9):820-3. Epub 2011 Jul 28.
146. Madan S, Lacy MQ, Dispenzieri A, Gertz MA, Buadi F, Hayman SR, Detweiler-Short K, Dingli D, Zeldenrust S, Lust J, Greipp PR, Rajkumar SV, **Kumar S**. Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma. *Blood*. 2011 Aug 18; 118(7):1763-5. Epub 2011 Jun 14.
147. **Kumar S**, Zhang MJ, Li P, Dispenzieri A, Milone GA, Lonial S, Krishnan A, Maiolino A, Wirk B, Weiss B, Freytes CO, Vogl DT, Vesole DH, Lazarus HM, Meehan KR, Hamadani M, Lill M, Callander NS, Majhail NS, Wiernik PH, Nath R, Kamble RT, Vij R, Kyle RA, Gale RP, Hari PN. Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis. *Blood*. 2011 Aug 18; 118(7):1979-88. Epub 2011 Jun 20.
148. **Kumar SK**, Lacy MQ, Hayman SR, Stewart K, Buadi FK, Allred J, Laumann K, Greipp PR, Lust JA, Gertz MA, Zeldenrust SR, Bergsagel PL, Reeder CB, Witzig TE, Fonseca R, Russell SJ, Mikhael JR, Dingli D, Rajkumar SV, Dispenzieri A. Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial. *Am J Hematol*. 2011 Aug; 86(8):640-5. Epub 2011 May 31.
149. Sinha S, Gastineau D, Micallef I, Hogan W, Ansell S, Buadi F, Dingli D, Dispenzieri A, Gertz M, Greiner C, Hayman S, Inwards D, Johnston P, Lacy M, Litzow M, Porrata L, Winters JL, **Kumar S**. Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention. *Bone Marrow Transplant*. 2011 Jul; 46(7):943-9. Epub 2010 Oct 11.
150. Gertz MA, Gastineau DA, Lacy MQ, Dispenzieri A, Hayman SR, **Kumar SK**, Dingli D, Leung N, Wolf RC, Hogan WJ, Buadi FK. SCT without growth factor in multiple myeloma: engraftment kinetics, bacteremia and hospitalization. *Bone Marrow Transplant*. 2011 Jul; 46(7):956-61. Epub 2010 Oct 25.
151. Gertz MA, Lacy MQ, Dispenzieri A, **Kumar SK**, Buadi FK, Dingli D, Leung N, Hogan WJ, Hayman SR. Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006. *Bone Marrow Transplant*. 2011 Jul; 46(7):970-5. Epub 2010 Oct 11.
152. **Kumar S**. Treatment of newly diagnosed multiple myeloma in transplant-eligible patients. *Curr Hematol Malig Rep*. 2011 Jun; 6(2):104-12.
153. Hutchison CA, Cockwell P, Stringer S, Bradwell A, Cook M, Gertz MA, Dispenzieri A, Winters JL, **Kumar S**, Rajkumar SV, Kyle RA, Leung N. Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. *J Am Soc Nephrol*. 2011 Jun; 22(6):1129-36. Epub 2011 Apr 21.
154. Patel B, Dey A, Ghorani E, **Kumar S**, Malam Y, Rai L, Steele AJ, Thomson J, Wickremasinghe RG, Zhang Y, Castleton AZ, Fielding AK. Differential cytopathology and kinetics of measles oncolysis in two primary B-cell malignancies provides mechanistic insights. *Mol Ther*. 2011 Jun; 19(6):1034-40. Epub 2011 Mar 22.

155. Herrmann SM, Gertz MA, Stegall MD, Dispenzieri A, Cosio FC, **Kumar S**, Lacy MQ, Dean PG, Prieto M, Zeldenrust SR, Buadi FK, Russell SJ, Nyberg SL, Hayman SR, Dingli D, Fervenza FC, Leung N. Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation. *Nephrol Dial Transplant*. 2011 Jun; 26(6):2032-6. Epub 2011 May 4
156. Dimopoulos M, Kyle R, Fermand JP, Rajkumar SV, San Miguel, Chanan-Khan A, Ludwig H, Joshua D, Mehta J, Gertz M, Avet-Loiseau H, Beksac M, Anderson KC, Moreau P, Singhal S, Goldschmidt H, Boccadoro M, **Kumar S**, Giral S, Munshi NC, Jagannath S, International Myeloma. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. *Blood*. 2011 May 5; 117(18):4701-5. Epub 2011 Feb 03.
157. **Kumar SK**, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Tan T, Sinha S, Leung N, Kyle RA, Rajkumar SV, Gertz MA. Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis. *Am J Hematol*. 2011 Mar; 86(3):251-5. Epub 2011 Feb 15.
158. Kyle RA, Dispenzieri A, **Kumar S**, Larson D, Therneau T, Rajkumar SV. IgM monoclonal gammopathy of undetermined significance (MGUS) and smoldering Waldenstrom's macroglobulinemia (SWM). *Clin Lymphoma Myeloma Leuk*. 2011 Feb; 11(1):74-6.
159. Siragusa S, Morice W, Gertz MA, Kyle RA, Greipp PR, Lust JA, Witzig TE, Lacy MQ, Zeldenrust SR, Rajkumar SV, Russell SJ, Hayman SR, Buadi F, **Kumar SK**, Dingli D, Dispenzieri A. Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature. *Ann Hematol*. 2011 Jan; 90(1):101-6. Epub 2010 Jul 20.
160. **Kumar SK**, Gertz MA, Lacy MQ, Dingli D, Hayman SR, Buadi FK, Short-Detweiler K, Zeldenrust SR, Leung N, Greipp PR, Lust JA, Russell SJ, Kyle RA, Rajkumar SV, Dispenzieri A. Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. *Mayo Clin Proc*. 2011 Jan; 86(1):12-8.
161. Madan S, **Kumar S**. Current treatment options for elderly patients with multiple myeloma: Clinical impact of novel agents. *Therapy*. 2011; 8(4):415-29.
162. **Kumar S**, Dispenzieri A, Katzmann JA, Larson DR, Colby CL, Lacy MQ, Hayman SR, Buadi FK, Leung N, Zeldenrust SR, Ramirez-Alvarado M, Clark RJ, Kyle RA, Rajkumar SV, Gertz MA. Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. *Blood*. 2010 Dec 9; 116(24):5126-9. Epub 2010 Aug 26.
163. Reece DE, Vesole DH, Shrestha S, Zhang MJ, Perez WS, Dispenzieri A, Milone GA, Abidi M, Atkins H, Bashey A, Bredeson CN, Boza WB, Freytes CO, Gale RP, Gajewski JL, Gibson J, Hale GA, **Kumar S**, Kyle RA, Lazarus HM, McCarthy PL, Pavlovsky S, Roy V, Weisdorf DJ, Wiernik PH, Hari PN. Outcome of patients with IgD and IgM multiple myeloma undergoing autologous hematopoietic stem cell transplantation: a retrospective CIBMTR study. *Clin Lymphoma Myeloma Leuk*. 2010 Dec; 10(6):458-63.
164. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, **Kumar SK**, Dingli D, Ansell SM, Gastineau DA, Inwards DJ, Johnston PB, Litzow MR, Micallef IN, Porrata LF, Leung N, Hogan WJ, Buadi FK. Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report. *Leuk Lymphoma*. 2010 Dec; 51(12):2181-7. Epub 2010 Oct 20.
165. Lacy MQ, Hayman SR, Gertz MA, Short KD, Dispenzieri A, **Kumar S**, Greipp PR, Lust JA, Russell SJ, Dingli D, Zeldenrust S, Fonseca R, Bergsagel PL, Roy V, Mikhael JR, Stewart AK, Laumann K, Allred JB, Mandrekar SJ, Rajkumar SV, Buadi F. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in

- lenalidomide refractory multiple myeloma (MM). *Leukemia*. 2010 Nov; 24(11):1934-9. Epub 2010 Sep 09.
166. Detweiler-Short K, Hayman S, Gertz MA, Lacy MQ, Dispenzieri A, **Kumar S**, Zeldenrust SR, Russell SJ, Lust JA, Kyle RA, Greipp PR, Witzig TE, Vincent Rajkumar S. Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma. *Am J Hematol*. 2010 Oct; 85(10):737-40.
167. Dispenzieri A, Dingli D, **Kumar SK**, Rajkumar SV, Lacy MQ, Hayman S, Buadi F, Zeldenrust S, Leung N, Detweiler-Short K, Lust JA, Russell SJ, Kyle RA, Gertz MA. Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs. *Am J Hematol*. 2010 Oct; 85(10):757-9.
168. Kapoor P, Greipp PT, Schaefer EW, Mandrekar SJ, Kamal AH, Gonzalez-Paz NC, **Kumar S**, Greipp PR. Idiopathic systemic capillary leak syndrome (Clarkson's disease): the Mayo clinic experience. *Mayo Clin Proc*. 2010 Oct; 85(10):905-12. Epub 2010 Jul 15.
169. Bianchi G, Kyle RA, Colby CL, Larson DR, **Kumar S**, Katzmann JA, Dispenzieri A, Therneau TM, Cerhan JR, Melton LJ 3rd, Rajkumar SV. Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications. *Blood*. 2010 Sep 23; 116(12):2019-25; quiz 2197. Epub 2010 May 21.
170. Gay F, Rajkumar SV, Coleman M, **Kumar S**, Mark T, Dispenzieri A, Pearse R, Gertz MA, Leonard J, Lacy MQ, Chen-Kiang S, Roy V, Jayabalan DS, Lust JA, Witzig TE, Fonseca R, Kyle RA, Greipp PR, Stewart AK, Niesvizky R. Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma. *Am J Hematol*. 2010 Sep; 85(9):664-9.
171. Ramakrishnan V, Kimlinger T, Haug J, Timm M, Wellik L, Halling T, Pardanani A, Tefferi A, Rajkumar SV, **Kumar S**. TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells. *Am J Hematol*. 2010 Sep; 85(9):675-86.
172. **Kumar S**, Kimlinger T, Morice W. Immunophenotyping in multiple myeloma and related plasma cell disorders. *Best Pract Res Clin Haematol*. 2010 Sep; 23(3):433-51.
173. Gay F, Vincent Rajkumar, Falco P, **Kumar S**, Dispenzieri A, Petrucci MT, Gertz MA, Boccadoro M, Keith Stewart, Palumbo A. Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma. *Eur J Haematol*. 2010 Sep; 85(3):200-8. Epub 2010 May 08.
174. Ansell SM, Kyle RA, Reeder CB, Fonseca R, Mikhael JR, Morice WG, Bergsagel PL, Buadi FK, Colgan JP, Dingli D, Dispenzieri A, Greipp PR, Habermann TM, Hayman SR, Inwards DJ, Johnston PB, **Kumar SK**, Lacy MQ, Lust JA, Markovic SN, Micallef IN, Nowakowski GS, Porrata LF, Roy V, Russell SJ, Short KE, Stewart AK, Thompson CA, Witzig TE, Zeldenrust SR, Dalton RJ, Rajkumar SV, Gertz MA. Diagnosis and management of Waldenstrom macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. *Mayo Clin Proc*. 2010 Sep; 85(9):824-33. Epub 2010 Aug 11.
175. Pavletic SZ, **Kumar S**, Mohty M, de Lima, Foran JM, Pasquini M, Zhang MJ, Giral S, Bishop MR, Weisdorf D. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation. *Biol Blood Marrow Transplant*. 2010 Jul; 16(7):871-90. Epub 2010 Apr 24.
176. **Kumar SK**, Flinn I, Noga SJ, Hari P, Rifkin R, Callander N, Bhandari M, Wolf JL,

Gasparetto C, Krishnan A, Grosman D, Glass J, Sahovic EA, Shi H, Webb IJ, Richardson PG, Rajkumar SV. Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study. *Leukemia*. 2010 Jul; 24(7):1350-6. Epub 2010 May 27.

177. Dispenzieri A, Wiseman GA, Lacy MQ, Hayman SR, **Kumar SK**, Buadi F, Dingli D, Laumann KM, Allred J, Geyer SM, Litzow MR, Gastineau DA, Inwards DJ, Micallef IN, Ansell SM, Porrata L, Elliott MA, Johnston PB, Hogan WJ, Gertz MA. A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. *Am J Hematol*. 2010 Jun; 85(6):409-13.
178. Stankowski-Drengler T, Gertz MA, Katzmann JA, Lacy MQ, **Kumar S**, Leung N, Hayman SR, Buadi F, Kyle RA, Rajkumar SV, Dispenzieri A. Serum immunoglobulin free light chain measurements and heavy chain isotype usage provide insight into disease biology in patients with POEMS syndrome. *Am J Hematol*. 2010 Jun; 85(6):431-4.
179. Kapoor P, Fonseca R, Rajkumar SV, Sinha S, Gertz MA, Stewart AK, Bergsagel PL, Lacy MQ, Dingli DD, Ketterling RP, Buadi F, Kyle RA, Witzig TE, Greipp PR, Dispenzieri A, **Kumar S**. Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapies. *Mayo Clin Proc*. 2010 Jun; 85(6):532-7.
180. **Kumar S**. Treatment of newly diagnosed multiple myeloma: advances in current therapy. *Med Oncol*. 2010 Jun; 27 Suppl 1:S14-24. Epub 2009 Dec 25.
181. Dispenzieri A, Katzmann JA, Kyle RA, Larson DR, Melton LJ 3rd, Colby CL, Therneau TM, Clark R, **Kumar SK**, Bradwell A, Fonseca R, Jelinek DF, Rajkumar SV. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. *Lancet*. 2010 May 15; 375(9727):1721-8.
182. **Kumar S**. Multiple myeloma - current issues and controversies. *Cancer Treat Rev*. 2010 May; 36 Suppl 2:S3-11.
183. Lorenz EC, Sethi S, Poshusta TL, Ramirez-Alvarado M, **Kumar S**, Lager DJ, Fervenza FC, Leung N. Renal failure due to combined cast nephropathy, amyloidosis and light-chain deposition disease. *Nephrol Dial Transplant*. 2010 Apr; 25(4):1340-3. Epub 2010 Jan 08.
184. Gertz MA, **Kumar S**, Lacy MQ, Dispenzieri A, Dingli D, Hayman SR, Buadi FK, Hogan WJ. Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction. *Blood*. 2010 Mar 25; 115(12):2348-53; quiz 2560. Epub 2010 Jan 20.
185. Dingli D, Tan TS, **Kumar SK**, Buadi FK, Dispenzieri A, Hayman SR, Lacy MQ, Gastineau DA, Hogan WJ, Gertz MA. Stem cell transplantation in patients with autonomic neuropathy due to primary (AL) amyloidosis. *Neurology*. 2010 Mar 16; 74(11):913-8.
186. **Kumar S**, Rajkumar SV. ASH 2009 meeting report-Top 10 clinically oriented abstracts in multiple myeloma. *Am J Hematol*. 2010 Mar; 85(3):210-3.
187. Sadek I, Kapoor P, Gertz MA, **Kumar S**. An unusual neurological complication of light chain amyloidosis. *Br J Haematol*. 2010 Mar; 148(6):816. Epub 2009 Sep 16.
188. Sinha S, Rajkumar SV, Lacy MQ, Hayman SR, Buadi FK, Dispenzieri A, Dingli D, Kyle RA, Gertz MA, **Kumar S**. Impact of dexamethasone responsiveness on long term outcome in patients with newly diagnosed multiple myeloma. *Br J Haematol*. 2010 Mar; 148(6):853-8. Epub 2009 Dec 03.
189. Madan S, Dispenzieri A, Lacy MQ, Buadi F, Hayman SR, Zeldenrust SR, Rajkumar SV,

- Gertz MA, **Kumar SK**. Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma. *Mayo Clin Proc*. 2010 Mar; 85(3):232-8.
190. Ramakrishnan V, Timm M, Haug JL, Kimlinger TK, Wellik LE, Witzig TE, Rajkumar SV, Adjei AA, **Kumar S**. Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs. *Oncogene*. 2010 Feb 25; 29(8):1190-202. Epub 2009 Nov 23.
191. Gay F, Hayman SR, Lacy MQ, Buadi F, Gertz MA, **Kumar S**, Dispenzieri A, Mikhael JR, Bergsagel PL, Dingli D, Reeder CB, Lust JA, Russell SJ, Roy V, Zeldenrust SR, Witzig TE, Fonseca R, Kyle RA, Greipp PR, Stewart AK, Rajkumar SV. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. *Blood*. 2010 Feb 18; 115(7):1343-50. Epub 2009 Dec 11.
192. Schaefer EW, **Kumar S**, Dispenzieri A, Allred JB, Gertz MA, Lacy MQ, Rajkumar SV, Mandrekar SJ. Residual serum monoclonal protein predicts progression-free survival in patients with previously untreated multiple myeloma. *Cancer*. 2010 Feb 1; 116(3):640-6.
193. Lacy MQ, Mandrekar S, Dispenzieri A, Hayman S, **Kumar S**, Buadi F, Dingli D, Litzow M, Wettstein P, Padley D, Kabat B, Gastineau D, Rajkumar SV, Gertz MA. Idiotypic-pulsed antigen-presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival. *Am J Hematol*. 2009 Dec; 84(12):799-802.
194. **Kumar SK**, Mikhael JR, Buadi FK, Dingli D, Dispenzieri A, Fonseca R, Gertz MA, Greipp PR, Hayman SR, Kyle RA, Lacy MQ, Lust JA, Reeder CB, Roy V, Russell SJ, Short KE, Stewart AK, Witzig TE, Zeldenrust SR, Dalton RJ, Rajkumar SV, Bergsagel PL. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. *Mayo Clin Proc*. 2009 Dec; 84(12):1095-110.
195. Lacy MQ, Hayman SR, Gertz MA, Dispenzieri A, Buadi F, **Kumar S**, Greipp PR, Lust JA, Russell SJ, Dingli D, Kyle RA, Fonseca R, Bergsagel PL, Roy V, Mikhael JR, Stewart AK, Laumann K, Allred JB, Mandrekar SJ, Rajkumar SV. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. *J Clin Oncol*. 2009 Oct 20; 27(30):5008-14. Epub 2009 Aug 31.
196. Chauhan D, Singh AV, Brahmandam M, Carrasco R, Bandi M, Hideshima T, Bianchi G, Podar K, Tai YT, Mitsiades C, Raje N, Jaye DL, **Kumar SK**, Richardson P, Munshi N, Anderson KC. Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. *Cancer Cell*. 2009 Oct 6; 16(4):309-23.
197. Gupta M, Ansell SM, Novak AJ, **Kumar S**, Kaufmann SH, Witzig TE. Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2. *Blood*. 2009 Oct 1; 114(14):2926-35. Epub 2009 Jul 29.
198. Gertz MA, Leung N, Lacy MQ, Dispenzieri A, Zeldenrust SR, Hayman SR, Buadi FK, Dingli D, Greipp PR, **Kumar SK**, Lust JA, Rajkumar SV, Russell SJ, Witzig TE. Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney. *Nephrol Dial Transplant*. 2009 Oct; 24(10):3132-7. Epub 2009 Apr 29.
199. Chee CE, **Kumar S**, Larson DR, Kyle RA, Dispenzieri A, Gertz MA, Colby CL, Rajkumar SV. The importance of bone marrow examination in determining complete response to therapy in patients with multiple myeloma. *Blood*. 2009 Sep 24; 114(13):2617-8. Epub 2009 Jul 29.
200. **Kumar S**, Giral S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, Comenzo RL, Lentzsch S, Munshi N, Niesvizky R, San Miguel J, Ludwig H, Bergsagel L, Blade J, Lonial S, Anderson KC, Tosi P, Sonneveld P, Sezer O, Vesole D, Cavo M, Einsele H,

Richardson PG, Durie BG, Rajkumar SV, International Myeloma Working Group. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. *Blood*. 2009 Aug 27; 114(9):1729-35. Epub 2009 Jun 26

201. Vachon CM, Kyle RA, Therneau TM, Foreman BJ, Larson DR, Colby CL, Phelps TK, Dispenzieri A, **Kumar SK**, Katzmman JA, Rajkumar SV. Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance. *Blood*. 2009 Jul 23; 114(4):785-90. Epub 2009 Jan 29.
202. Kapoor P, **Kumar S**, Fonseca R, Lacy MQ, Witzig TE, Hayman SR, Dispenzieri A, Buadi F, Bergsagel PL, Gertz MA, Dalton RJ, Mikhael JR, Dingli D, Reeder CB, Lust JA, Russell SJ, Roy V, Zeldenrust SR, Stewart AK, Kyle RA, Greipp PR, Rajkumar SV. Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. *Blood*. 2009 Jul 16; 114(3):518-21. Epub 2009 Mar 26.
203. Ng AC, **Kumar SK**, Rajkumar SV, Drake MT. Impact of vitamin D deficiency on the clinical presentation and prognosis of patients with newly diagnosed multiple myeloma. *Am J Hematol*. 2009 Jul; 84(7):397-400.
204. Peng KW, Dogan A, Vrana J, Liu C, Ong HT, **Kumar S**, Dispenzieri A, Dietz AB, Russell SJ. Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma. *Am J Hematol*. 2009 Jul; 84(7):401-7.
205. Chen C, Reece DE, Siegel D, Niesvizky R, Boccia RV, Stadtmauer EA, Abonour R, Richardson P, Matous J, **Kumar S**, Bahlis NJ, Alsina M, Vescio R, Coutre SE, Pietronigro D, Knight RD, Zeldis JB, Rajkumar V. Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. *Br J Haematol*. 2009 Jul; 146(2):164-70. Epub 2009 May 26.
206. Landgren O, Kyle RA, Pfeiffer RM, Katzmman JA, Caporaso NE, Hayes RB, Dispenzieri A, **Kumar S**, Clark RJ, Baris D, Hoover R, Rajkumar SV. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. *Blood*. 2009 May 28; 113(22):5412-7. Epub 2009 Jan 29.
207. Costa LJ, **Kumar S**, Dispenzieri A, Hayman SE, Buadi FK, Dingli D, Litzow MR, Gertz MA, Lacy MQ. Factors associated with favorable outcome after allogeneic hematopoietic stem cell transplantation for multiple myeloma. *Leuk Lymphoma*. 2009 May; 50(5):781-7.
208. Gertz MA, **Kumar SK**, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK, Dingli D, Gastineau DA, Winters JL, Litzow MR. Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma. *Bone Marrow Transplant*. 2009 Apr; 43(8):619-25. Epub 2008 Nov 10.
209. **Kumar S**. Stem cell transplantation for multiple myeloma. *Curr Opin Oncol*. 2009 Mar; 21(2):162-70.
210. Bryce AH, Ketterling RP, Gertz MA, Lacy M, Knudson RA, Zeldenrust S, **Kumar S**, Hayman S, Buadi F, Kyle RA, Greipp PR, Lust JA, Russell S, Rajkumar SV, Fonseca R, Dispenzieri A. Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis. *Haematologica*. 2009 Mar; 94(3):380-6. Epub 2009 Feb 11.
211. Lust JA, Lacy MQ, Zeldenrust SR, Dispenzieri A, Gertz MA, Witzig TE, **Kumar S**, Hayman SR, Russell SJ, Buadi FK, Geyer SM, Campbell ME, Kyle RA, Rajkumar SV, Greipp PR, Kline MP, Xiong Y, Moon-Tasson LL, Donovan KA. Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. *Mayo Clin Proc*. 2009 Feb; 84(2):114-22.

212. Patra CR, Verma R, **Kumar S**, Greipp PR, Mukhopadhyay D, Mukherjee P. Fabrication of gold nanoparticle for potential application in multiple myeloma. *J Biomed Nanotechnol*. 2008 Dec; 4(4):499-507.
213. Bryce AH, Ketterling RP, Gertz MA, Lacy M, Knudson RA, **Kumar S**, Kyle RA, Fonseca R, Greipp PR, Lust JA, Rajkumar VS, Hayman SR, Buadi F, Russell SJ, Zeldenrust SR, Dispenzieri A. A novel report of cig-FISH and cytogenetics in POEMS syndrome. *Am J Hematol*. 2008 Nov; 83(11):840-1.
214. **Kumar S**, Perez WS, Zhang MJ, Ballen K, Bashey A, To LB, Bredeson CN, Cairo MS, Effenbein GJ, Freytes CO, Gale RP, Gibson J, Kyle RA, Lacy MQ, Lazarus HM, McCarthy PL, Milone GA, Moreb JS, Pavlovsky S, Reece DE, Vesole DH, Wiernik PH, Hari P. Comparable outcomes in nonsecretory and secretory multiple myeloma after autologous stem cell transplantation. *Biol Blood Marrow Transplant*. 2008 Oct; 14(10):1134-40.
215. Snozek CL, Katzmann JA, Kyle RA, Dispenzieri A, Larson DR, Therneau TM, Melton LJ 3rd, **Kumar S**, Greipp PR, Clark RJ, Rajkumar SV. Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. *Leukemia*. 2008 Oct; 22(10):1933-7. Epub 2008 Jul 03.
216. Gertz MA, Ansell SM, Dingli D, Dispenzieri A, Buadi FK, Elliott MA, Gastineau DA, Hayman SR, Hogan WJ, Inwards DJ, Johnston PB, **Kumar S**, Lacy MQ, Leung N, Micallef IN, Porrata LF, Schafer BA, Wolf RC, Litzow MR. Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative. *Mayo Clin Proc*. 2008 Oct; 83(10):1131-8.
217. **Kumar S**, Mahmood ST, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK, Dingli D, Rajkumar SV, Litzow MR, Gertz MA. Impact of early relapse after auto-SCT for multiple myeloma. *Bone Marrow Transplant*. 2008 Sep; 42(6):413-20. Epub 2008 Jun 30.
218. **Kumar SK**, Dingli D, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK, Rajkumar SV, Litzow MR, Gertz MA. Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis. *Am J Hematol*. 2008 Aug; 83(8):614-7.
219. **Kumar S**, Dingli D, Dispenzieri A, Lacy M, Hayman SR, Buadi F, Rajkumar S, Litzow M, Gertz M. Impact of additional cytoreduction following autologous SCT in multiple myeloma. *Bone Marrow Transplant*. 2008 Aug; 42(4):259-64. Epub 2008 Jun 16.
220. Shaikh A, Habermann TM, Fidler ME, **Kumar S**, Leung N. Acute renal failure secondary to severe type I cryoglobulinemia following rituximab therapy for Waldenstrom's macroglobulinemia. *Clin Exp Nephrol*. 2008 Aug; 12(4):292-5. Epub 2008 Feb 22.
221. Lacy MQ, Dispenzieri A, Hayman SR, **Kumar S**, Kyle RA, Rajkumar SV, Edwards BS, Rodeheffer RJ, Frantz RP, Kushwaha SS, Clavell AL, Dearani JA, Sundt TM, Daly RC, McGregor CG, Gastineau DA, Litzow MR, Gertz MA. Autologous stem cell transplant after heart transplant for light chain (AL) amyloid cardiomyopathy. *J Heart Lung Transplant*. 2008 Aug; 27(8):823-9. Epub 2008 Jul 03.
222. Wang L, **Kumar S**, Fridley BL, Kalari KR, Moon I, Pelleymounter LL, Hildebrandt MA, Batzler A, Eckloff BW, Wieben ED, Greipp PR. Proteasome beta subunit pharmacogenomics: gene resequencing and functional genomics. *Clin Cancer Res*. 2008 Jun 1; 14(11):3503-13.
223. **Kumar SK**, Dingli D, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Rajkumar SV, Litzow MR, Gertz MA. Impact of pretransplant therapy in patients with newly diagnosed myeloma undergoing autologous SCT. *Bone Marrow Transplant*. 2008 Jun; 41(12):1013-9. Epub 2008 Mar 10.

224. Ege H, Gertz MA, Markovic SN, Lacy MQ, Dispenzieri A, Hayman SR, **Kumar SK**, Porrata LF. Prediction of survival using absolute lymphocyte count for newly diagnosed patients with multiple myeloma: a retrospective study. *Br J Haematol*. 2008 Jun; 141(6):792-8. Epub 2008 Apr 10.
225. Simpson L, **Kumar SK**, Okuno SH, Schaff HV, Porrata LF, Buckner JC, Moynihan TJ. Malignant primary cardiac tumors: review of a single institution experience. *Cancer*. 2008 Jun; 112(11):2440-6.
226. Leung N, Gertz MA, Zeldenrust SR, Rajkumar SV, Dispenzieri A, Fervenza FC, **Kumar S**, Lacy MQ, Lust JA, Greipp PR, Witzig TE, Hayman SR, Russell SJ, Kyle RA, Winters JL. Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. *Kidney Int*. 2008 Jun; 73(11):1282-8. Epub 2008 Apr 02.
227. Dispenzieri A, Lacy MQ, Hayman SR, **Kumar SK**, Buadi F, Dingli D, Litzow MR, Gastineau DA, Inwards DJ, Elliott MA, Micallef IN, Ansell SM, Hogan WJ, Porrata LF, Johnston PA, Afessa B, Bryce A, Kyle RA, Gertz MA. Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome. *Eur J Haematol*. 2008 May; 80(5):397-406. Epub 2008 Jan 23.
228. Kline MP, Rajkumar SV, Timm MM, Kimlinger TK, Haug JL, Lust JA, Greipp PR, **Kumar S**. R-(-)-gossypol (AT-101) activates programmed cell death in multiple myeloma cells. *Exp Hematol*. 2008 May; 36(5):568-76. Epub 2008 Mar 17.
229. **Kumar SK**, Dingli D, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK, Rajkumar SV, Litzow MR, Gertz MA. Outcome after autologous stem cell transplantation for multiple myeloma in patients with preceding plasma cell disorders. *Br J Haematol*. 2008 Apr; 141(2):205-11. Epub 2008 Mar 03.
230. **Kumar S**. Role of allogeneic stem cell transplantation in multiple myeloma. *Curr Hematol Malig Rep*. 2008 Apr; 3(2):99-106.
231. **Kumar SK**, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, Greipp PR, Kyle RA, Gertz MA. Improved survival in multiple myeloma and the impact of novel therapies. *Blood*. 2008 Mar 1; 111(5):2516-20. Epub 2007 Nov 01.
232. **Kumar S**, Dispenzieri A, Lacy MQ, Hayman SR, Leung N, Zeldenrust SR, Buadi FK, Kyle RA, Rajkumar SV, Gertz MA. Serum uric acid: novel prognostic factor in primary systemic amyloidosis. *Mayo Clin Proc*. 2008 Mar; 83(3):297-303.
233. Dispenzieri A, Kyle RA, Katzmann JA, Therneau TM, Larson D, Benson J, Clark RJ, Melton LJ 3rd, Gertz MA, **Kumar SK**, Fonseca R, Jelinek DF, Rajkumar SV. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. *Blood*. 2008 Jan 15; 111(2):785-9. Epub 2007 Oct 17.
234. Gertz M, Lacy M, Dispenzieri A, Hayman S, **Kumar S**, Buadi F, Leung N, Litzow M. Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis. *Leuk Lymphoma*. 2008 Jan; 49(1):36-41.
235. **Kumar SK**, Hayman SR, Kyle RA. Autologous stem cell transplantation in the elderly including pre- and post-treatment options. *Bone Marrow Transplant*. 2007 Dec; 40(12):1115-21. Epub 2007 Aug 06.
236. Dingli D, Pacheco JM, Nowakowski GS, **Kumar SK**, Dispenzieri A, Hayman SR, Lacy MQ, Gastineau DA, Gertz MA. Relationship between depth of response and outcome in multiple myeloma. *J Clin Oncol*. 2007 Nov 1; 25(31):4933-7.

237. **Kumar S**. Lenalidomide with or without dexamethasone for relapsed or refractory multiple myeloma. *Am J Hematol Oncol*. 2007 Nov; 6(11):644-5, 650.
238. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, **Kumar SK**, Leung N, Gastineau DA. Transplantation without growth factor: engraftment kinetics after stem cell transplantation for primary systemic amyloidosis (AL). *Bone Marrow Transplant*. 2007 Nov; 40(10):989-93. Epub 2007 Sep 10.
239. Meng XW, Lee SH, Dai H, Loegering D, Yu C, Flatten K, Schneider P, Dai NT, **Kumar SK**, Smith BD, Karp JE, Adjei AA, Kaufmann SH. Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization. *J Biol Chem*. 2007 Oct 12; 282(41):29831-46. Epub 2007 Aug 13.
240. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, **Kumar SK**, Leung N, Gastineau DA. Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response. *Haematologica*. 2007 Oct; 92(10):1415-8.
241. Lacy MQ, Gertz MA, Dispenzieri A, Hayman SR, Geyer S, Kabat B, Zeldenrust SR, **Kumar S**, Greipp PR, Fonseca R, Lust JA, Russell SJ, Kyle RA, Witzig TE, Bergsagel PL, Stewart AK, Rajkumar SV. Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. *Mayo Clin Proc*. 2007 Oct; 82(10):1179-84.
242. **Kumar S**, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Gastineau DA, Litzow MR, Fonseca R, Roy V, Rajkumar SV, Gertz MA. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. *Leukemia*. 2007 Sep; 21(9):2035-42. Epub 2007 Jun 21.
243. Morice WG, Hanson CA, **Kumar S**, Frederick LA, Lesnick CE, Greipp PR. Novel multi-parameter flow cytometry sensitively detects phenotypically distinct plasma cell subsets in plasma cell proliferative disorders. *Leukemia*. 2007 Sep; 21(9):2043-6. Epub 2007 Apr 26.
244. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ, Van Wier S, Tiedemann R, Shi CX, Sebag M, Braggio E, Henry T, Zhu YX, Fogle H, Price-Troska T, Ahmann G, Mancini C, Brents LA, **Kumar S**, Greipp P, Dispenzieri A, Bryant B, Mulligan G, Bruhn L, Barrett M, Valdez R, Trent J, Stewart AK, Carpten J, Bergsagel PL. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. *Cancer Cell*. 2007 Aug; 12(2):131-44.
245. Dingli D, Pacheco JM, Dispenzieri A, Hayman SR, **Kumar SK**, Lacy MQ, Gastineau DA, Gertz MA. Serum M-spike and transplant outcome in patients with multiple myeloma. *Cancer Sci*. 2007 Jul; 98(7):1035-40. Epub 2007 May 04.
246. Kline MP, Rajkumar SV, Timm MM, Kimlinger TK, Haug JL, Lust JA, Greipp PR, **Kumar S**. ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells. *Leukemia*. 2007 Jul; 21(7):1549-60. Epub 2007 Apr 26.
247. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, **Kumar S**, Leung N, Gastineau DA. Impact of age and serum creatinine value on outcome after autologous blood stem cell transplantation for patients with multiple myeloma. *Bone Marrow Transplant*. 2007 May; 39(10):605-11. Epub 2007 Mar 19.
248. Dingli D, Pacheco JM, Dispenzieri A, Hayman SR, **Kumar SK**, Lacy MQ, Gastineau DA, Gertz MA. In vivo and in silico studies on single versus multiple transplants for multiple myeloma. *Cancer Sci*. 2007 May; 98(5):734-9. Epub 2007 Mar 14.

249. Leung N, Dispenzieri A, Lacy MQ, **Kumar SK**, Hayman SR, Fervenza FC, Cha SS, Gertz MA. Severity of baseline proteinuria predicts renal response in immunoglobulin light chain-associated amyloidosis after autologous stem cell transplantation. *Clin J Am Soc Nephrol*. 2007 May; 2(3):440-4. Epub 2007 Apr 04.
250. **Kumar S**. Role of autologous stem cell transplantation in multiple myeloma. *Curr Hematol Malig Rep*. 2007 May; 2(2):121-7.
251. Kline M, Donovan K, Wellik L, Lust C, Jin W, Moon-Tasson L, Xiong Y, Witzig TE, **Kumar S**, Rajkumar SV, Lust JA. Cytokine and chemokine profiles in multiple myeloma; significance of stromal interaction and correlation of IL-8 production with disease progression. *Leuk Res*. 2007 May; 31(5):591-8.
252. Chng WJ, **Kumar S**, Vanwier S, Ahmann G, Price-Troska T, Henderson K, Chung TH, Kim S, Mulligan G, Bryant B, Carpten J, Gertz M, Rajkumar SV, Lacy M, Dispenzieri A, Kyle R, Greipp P, Bergsagel PL, Fonseca R. Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. *Cancer Res*. 2007 Apr 1; 67(7):2982-9.
253. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, **Kumar S**. Transplantation for amyloidosis. *Curr Opin Oncol*. 2007 Mar; 19(2):136-41.
254. Stewart AK, Bergsagel PL, Greipp PR, Dispenzieri A, Gertz MA, Hayman SR, **Kumar S**, Lacy MQ, Lust JA, Russell SJ, Witzig TE, Zeldenrust SR, Dingli D, Reeder CB, Roy V, Kyle RA, Rajkumar SV, Fonseca R. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. *Leukemia*. 2007 Mar; 21(3):529-34. Epub 2007 Jan 18.
255. Dispenzieri A, Rajkumar SV, Gertz MA, Fonseca R, Lacy MQ, Bergsagel PL, Kyle RA, Greipp PR, Witzig TE, Reeder CB, Lust JA, Russell SJ, Hayman SR, Roy V, **Kumar S**, Zeldenrust SR, Dalton RJ, Stewart AK. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. *Mayo Clin Proc*. 2007 Mar; 82(3):323-41.
256. Bhattacharya R, Patra CR, Verma R, **Kumar S**, Greipp PR, Mukherjee P. Gold Nanoparticles Inhibit the Proliferation of Multiple Myeloma Cells. *Advanced Materials*. 2007 Feb; 19(5):711-6.
257. Dispenzieri A, Lacy MQ, Zeldenrust SR, Hayman SR, **Kumar SK**, Geyer SM, Lust JA, Allred JB, Witzig TE, Rajkumar SV, Greipp PR, Russell SJ, Kabat B, Gertz MA. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. *Blood*. 2007 Jan 15; 109(2):465-70. Epub 2006 Sep 28.
258. Podar K, Tonon G, Sattler M, Tai YT, Legouill S, Yasui H, Ishitsuka K, **Kumar S**, Kumar R, Pandite LN, Hideshima T, Chauhan D, Anderson KC. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. *Proc Natl Acad Sci U S A*. 2006 Dec 19; 103(51):19478-83. Epub 2006 Dec 12.
259. Raje N, **Kumar S**, Hideshima T, Ishitsuka K, Yasui H, Chhetri S, Vallet S, Vonescu E, Shiraishi N, Kiziltepe T, Elford HL, Munshi NC, Anderson KC. Didox, a ribonucleotide reductase inhibitor, induces apoptosis and inhibits DNA repair in multiple myeloma cells. *Br J Haematol*. 2006 Oct; 135(1):52-61. Epub 2006 Aug 22.
260. Timm MM, Kimlinger TK, Haug JL, Kline MP, Greipp PR, Rajkumar SV, **Kumar SK**. Thymoglobulin targets multiple plasma cell antigens and has in vitro and in vivo activity in multiple myeloma. *Leukemia*. 2006 Oct; 20(10):1863-9. Epub 2006 Aug 17.
261. Bryce AH, Dispenzieri A, Kyle RA, Lacy MQ, Rajkumar SV, Inwards DJ, Yasenchak CA, **Kumar SK**, Gertz MA. Response to rituximab in patients with type II cryoglobulinemia. *Clin Lymphoma Myeloma*. 2006 Sep; 7(2):140-4.

262. Kimlinger T, Kline M, **Kumar S**, Lust J, Witzig T, Rajkumar SV. Differential expression of vascular endothelial growth factors and their receptors in multiple myeloma. *Haematologica*. 2006 Aug; 91(8):1033-40. Epub 2006 Jul 25.
263. Lacy MQ, Dispenzieri A, Gertz MA, Greipp PR, Gollbach KL, Hayman SR, **Kumar S**, Lust JA, Rajkumar SV, Russell SJ, Witzig TE, Zeldenrust SR, Dingli D, Bergsagel PL, Fonseca R, Reeder CB, Stewart AK, Roy V, Dalton RJ, Carr AB, Kademani D, Keller EE, Viozzi CF, Kyle RA. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. *Mayo Clin Proc*. 2006 Aug; 81(8):1047-53.
264. **Kumar S**, Rajkumar SV. Thalidomide and lenalidomide in the treatment of multiple myeloma. *Eur J Cancer*. 2006 Jul; 42(11):1612-22. Epub 2006 Jun 05.
265. Chng WJ, Ahmann GJ, Henderson K, Santana-Davila R, Greipp PR, Gertz MA, Lacy MQ, Dispenzieri A, **Kumar S**, Rajkumar SV, Lust JA, Kyle RA, Zeldenrust SR, Hayman SR, Fonseca R. Clinical implication of centrosome amplification in plasma cell neoplasm. *Blood*. 2006 May 1; 107(9):3669-75. Epub 2005 Dec 22.
266. Dispenzieri A, Lacy MQ, Katzmann JA, Rajkumar SV, Abraham RS, Hayman SR, **Kumar SK**, Clark R, Kyle RA, Litzow MR, Inwards DJ, Ansell SM, Micallef IM, Porrata LF, Elliott MA, Johnston PB, Greipp PR, Witzig TE, Zeldenrust SR, Russell SJ, Gastineau D, Gertz MA. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. *Blood*. 2006 Apr 15; 107(8):3378-83. Epub 2006 Jan 05.
267. **Kumar S**, Raje N, Hideshima T, Ishitsuka K, Podar K, Le Gouille S, Chauhan D, Richardson P, Munshi NC, Anderson K. FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myeloma. *Br J Haematol*. 2006 Mar; 132(6):698-704.
268. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, **Kumar SK**. High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with multiple myeloma. *Expert Rev Anticancer Ther*. 2006 Mar; 6(3):343-60.
269. Roccaro AM, Hideshima T, Raje N, **Kumar S**, Ishitsuka K, Yasui H, Shiraishi N, Ribatti D, Nico B, Vacca A, Dammacco F, Richardson PG, Anderson KC. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. *Cancer Res*. 2006 Jan 1; 66(1):184-91.
270. Rajkumar SV, Hayman SR, Lacy MQ, Dispenzieri A, Geyer SM, Kabat B, Zeldenrust SR, **Kumar S**, Greipp PR, Fonseca R, Lust JA, Russell SJ, Kyle RA, Witzig TE, Gertz MA. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. *Blood*. 2005 Dec 15; 106(13):4050-3. Epub 2005 Aug 23.
271. Lacy MQ, Hogan WJ, Gertz MA, Dispenzieri A, Rajkumar SV, Hayman S, **Kumar S**, Litzow MR, Schroeter AL. Successful treatment of scleromyxedema with autologous peripheral blood stem cell transplantation. *Arch Dermatol*. 2005 Oct; 141(10):1277-82.
272. **Kumar S**, Rajkumar SV. Thalidomide and dexamethasone: therapy for multiple myeloma. *Expert Rev Anticancer Ther*. 2005 Oct; 5(5):759-66.
273. **Kumar S**, Rajkumar SV, Kyle RA, Lacy MQ, Dispenzieri A, Fonseca R, Lust JA, Gertz MA, Greipp PR, Witzig TE. Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance. *Journal of Clinical Oncology*. 2005 Aug 20; 23(24):5668-74.
274. Raje N, **Kumar S**, Hideshima T, Roccaro A, Ishitsuka K, Yasui H, Shiraishi N, Chauhan D, Munshi NC, Green SR, Anderson KC. Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. *Blood*. 2005 Aug 1; 106(3):1042-7.

275. **Kumar S**, Rajkumar SV, Kimlinger T, Greipp PR, Witzig TE. CD45 expression by bone marrow plasma cells in multiple myeloma: clinical and biological correlations. *Leukemia*. 2005 Aug; 19(8):1466-70.
276. **Kumar S**, Anderson KC. Drug insight: thalidomide as a treatment for multiple myeloma. *Nat Clin Pract Oncol*. 2005 May; 2(5):262-70.
277. **Kumar S**, Rajkumar SV, Greipp PR, Witzig TE. Cell proliferation of myeloma plasma cells: Comparison of the blood and marrow compartments. *Am J Hematol*. 2004 Sep; 77(1):7-11.
278. **Kumar S**, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Geyer S, Allmer C, Witzig TE, Lust JA, Greipp PR, Kyle RA, Litzow MR, Gertz MA. Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma. *Bone Marrow Transplant*. 2004 Sep; 34(6):485-90.
279. **Kumar S**, Witzig TE, Timm M, Haug J, Wellik L, Kimlinger TK, Greipp PR, Rajkumar SV. Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression. *Blood*. 2004 Aug 15; 104(4):1159-65. Epub 2004 May 06.
280. **Kumar S**, Gertz MA, Dispenzieri A, Lacy MQ, Wellik LA, Fonseca R, Lust JA, Witzig TE, Kyle RA, Greipp PR, Rajkumar SV. Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy. *Bone Marrow Transplant*. 2004 Aug; 34(3):235-9.
281. **Kumar S**, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Geyer S, Allmer C, Witzig TE, Lust JA, Greipp PR, Kyle RA, Litzow MR, Gertz MA. High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy. *Bone Marrow Transplant*. 2004 Jul; 34(2):161-7.
282. **Kumar SK**, Therneau TM, Gertz MA, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Witzig TE, Lust JA, Larson DR, Kyle RA, Greipp PR. Clinical course of patients with relapsed multiple myeloma. *Mayo Clin Proc*. 2004 Jul; 79(7):867-74.
283. **Kumar S**, Witzig TE, Rajkumar SV. Thalidomid: current role in the treatment of non-plasma cell malignancies. *J Clin Oncol*. 2004 Jun 15; 22(12):2477-88.
284. **Kumar S**, Witzig TE, Dispenzieri A, Lacy MQ, Wellik LE, Fonseca R, Lust JA, Gertz MA, Kyle RA, Greipp PR, Rajkumar SV. Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma. *Leukemia*. 2004 Mar; 18(3):624-7.
285. Raje N, **Kumar S**, Hideshima T, et al. Combination of the mTOR inhibitor Rapamycin and Revlimid(TM)(CC-5013) has synergistic activity in multiple myeloma. *Blood*. 2004.
286. Huber MR, **Kumar S**, Tefferi A. Treatment advances in adult immune thrombocytopenic purpura. *Ann Hematol*. 2003 Dec; 82(12):723-37.
287. **Kumar S**, Litzow MR, Rajkumar SV. Effect of allogeneic stem cell transplantation on bone marrow angiogenesis in chronic myelogenous leukemia. *Bone Marrow Transplant*. 2003 Dec; 32(11):1065-9.
288. Thompson MA, Witzig TE, **Kumar S**, Timm MM, Haug J, Fonseca R, Greipp PR, Lust JA, Rajkumar SV. Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma. *Br J Haematol*. 2003 Oct; 123(2):305-8.
289. **Kumar S**, Witzig TE, Timm M, Haug J, Wellik L, Fonseca R, Greipp PR, Rajkumar SV. Expression of VEGF and its receptors by myeloma cells. *Leukemia*. 2003 Oct; 17(10):2025-31.

290. **Kumar S**, Chen MG, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, Tefferi A, Litzow MR. Lymphocyte recovery after allogeneic bone marrow transplantation predicts risk of relapse in acute lymphoblastic leukemia. *Leukemia*. 2003 Sep; 17(9):1865-70.
291. **Kumar S**, Kimlinger TK, Lust JA, Donovan K, Witzig TE. Expression of CD52 on plasma cells in plasma cell proliferative disorders. *Blood*. 2003 Aug 1; 102(3):1075-7. Epub 2003 Apr 24.
292. **Kumar S**, Witzig TE, Greipp PR, Rajkumar SV. Bone marrow angiogenesis and circulating plasma cells in multiple myeloma. *Br J Haematol*. 2003 Jul; 122(2):272-4.
293. **Kumar S**, Kamath PS. Acute superior mesenteric venous thrombosis: One disease or two? *Am J Gastroenterol*. 2003 Jun; 98(6):1299-304.
294. Jatoi A, **Kumar S**, Sloan JA, Nguyen PL. On appetite and its loss. *J Clin Oncol*. 2003 May 1; 21(9 Suppl):79s-81s.
295. **Kumar S**, DeLeve LD, Kamath PS, Tefferi A. Hepatic veno-occlusive disease (sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation. *Mayo Clin Proc*. 2003 May; 78(5):589-98.
296. **Kumar S**, Pruthi RK, Nichols WL. Acquired von Willebrand's syndrome: a single institution experience. *Am J Hematol*. 2003 Apr; 72(4):243-7.
297. Rajkumar SV, Gertz MA, Lacy MQ, Dispenzieri A, Fonseca R, Geyer SM, Iturria N, **Kumar S**, Lust JA, Kyle RA, Greipp PR, Witzig TE. Thalidomide as initial therapy for early-stage myeloma. *Leukemia*. 2003 Apr; 17(4):775-9.
298. **Kumar S**, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Wellik L, Witzig TE, Gertz MA, Kyle RA, Greipp PR, Rajkumar SV. Prognostic value of angiogenesis in solitary bone plasmacytoma. *Blood*. 2003 Mar 1; 101(5):1715-7.
299. **Kumar S**, Gertz MA, Dispenzieri A, Lacy MQ, Geyer SM, Iturria NL, Fonseca R, Hayman SR, Lust JA, Kyle RA, Greipp PR, Witzig TE, Rajkumar SV. Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. *Mayo Clin Proc*. 2003 Jan; 78(1):34-9.
300. Bucheit AD, **Kumar S**, Grote DM, Lin YK, von Messling V, Cattaneo RB, Fielding AK. An oncolytic measles virus engineered to enter cells through the CD20 antigen. *Molecular Therapy: the Journal of the American Society of Gene Therapy*. 2003 Jan; 7(1):62-72.
301. **Kumar S**, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Gertz MA, Kyle RA, Greipp PR, Rajkumar SV. Bone marrow angiogenesis in multiple myeloma: effect of therapy. *Br J Haematol*. 2002 Dec; 119(3):665-71.
302. **Kumar S**, Wolf RC, Chen MG, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, Tefferi A, Litzow MR. Omission of day +11 methotrexate after allogeneic bone marrow transplantation is associated with increased risk of severe acute graft-versus-host disease. *Bone Marrow Transplant*. 2002 Aug; 30(3):161-5.
303. Porrata LF, Litzow MR, Tefferi A, Letendre L, **Kumar S**, Geyer SM, Markovic SN. Early lymphocyte recovery is a predictive factor for prolonged survival after autologous hematopoietic stem cell transplantation for acute myelogenous leukemia. *Leukemia*. 2002 Jul; 16(7):1311-8.
304. **Kumar S**, Diehn FE, Gertz MA, Tefferi A. Splenectomy for immune thrombocytopenic purpura: long-term results and treatment of postsplenectomy relapses. *Ann Hematol*. 2002 Jun; 81(6):312-9.

305. **Kumar S**, Menke DM, Dewald GW, Colon-Otero G. Agnogenic myeloid metaplasia associated with Klinefelter syndrome: a case report. *Ann Hematol.* 2002 Apr; 81(4):215-8. Epub 2002 Mar 07.
306. **Kumar S**, Witzig TE, Rajkumar SV. Thalidomide as an anti-cancer agent. *J Cell Mol Med.* 2002 Apr-Jun; 6(2):160-74.
307. **Kumar S**, Pruthi RK, Nichols WL. Acquired von Willebrand disease. *Mayo Clin Proc.* 2002 Feb; 77(2):181-7.
308. **Kumar S**, Sarr MG, Kamath PS. Mesenteric venous thrombosis. *N Engl J Med.* 2001 Dec 6; 345(23):1683-8.
309. **Kumar S**, Chen MG, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, Tefferi A, Litzow MR. Effect of slow lymphocyte recovery and type of graft-versus-host disease prophylaxis on relapse after allogeneic bone marrow transplantation for acute myelogenous leukemia. *Bone Marrow Transplant.* 2001 Nov; 28(10):951-6.
310. Tefferi A, **Kumar S**, Wolf RC, Lacy MQ, Inwards DJ, Gloor JM, Albright RC, Kamath PS, Litzow MR. Charcoal hemofiltration for hepatic veno-occlusive disease after hematopoietic stem cell transplantation. *Bone Marrow Transplant.* 2001 Nov; 28(10):997-9.
311. **Kumar S**, Dispenzieri A, Lacy MQ, Litzow MR, Gertz MA. High incidence of gastrointestinal tract bleeding after autologous stem cell transplant for primary systemic amyloidosis. *Bone Marrow Transplant.* 2001 Aug; 28(4):381-5.
312. **Kumar S**, Tefferi A. Spontaneous pneumomediastinum and subcutaneous emphysema complicating bronchiolitis obliterans after allogeneic bone marrow transplantation--case report and review of literature. *Ann Hematol.* 2001 Jul; 80(7):430-5.
313. **Kumar S**, Chen MG, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, Tefferi A, Harmsen WS, Litzow MR. Prophylaxis of graft-versus-host disease with cyclosporine-prednisone is associated with increased risk of chronic graft-versus-host disease. *Bone Marrow Transplant.* 2001 Jun; 27(11):1133-40.
314. Capizzi SA, **Kumar S**, Huneke NE, Gertz MA, Inwards DJ, Litzow MR, Lacy MQ, Gastineau DA, Prakash UB, Tefferi A. Peri-engraftment respiratory distress syndrome during autologous hematopoietic stem cell transplantation. *Bone Marrow Transplant.* 2001 Jun; 27(12):1299-303.
315. **Kumar SK**, Goldberg RM. Adjuvant chemotherapy for colon cancer. *Curr Oncol Rep.* 2001 Mar; 3(2):94-101.
316. **Kumar S**, Lacy MQ. 59-year-old man with pelvic pain and hypergammaglobulinemia. *Mayo Clin Proc.* 2001 Mar; 76(3):311-4.
317. Jatoi A, **Kumar S**, Sloan JA, Nguyen PL. On appetite and its loss. *J Clin Oncol.* 2000 Aug; 18(15):2930-2.
318. **Kumar S**, Mow BM, Kaufmann SH. Hypercalcemia complicating leukemic transformation of agnogenic myeloid metaplasia-myelofibrosis. *Mayo Clin Proc.* 1999 Dec; 74(12):1233-7.
319. Guleria R, **Kumar S**, Agarwal S, Prasad L. Renal failure with skeletal abnormalities. *Postgrad Med J.* 1996; 72:569-570.

Books

1. **Kumar S.** Multiple Myeloma Kumar S. Vol. 1. New York (NY): Demos Medical; 2010. (Emerging Cancer Therapeutics) (Book)

Book Chapters

1. **Kumar S**, McCurdy A. New agents for multiple myeloma. In: Gertz MA; Rajkumar SV editor. Multiple myeloma: diagnosed and treatment. New York: Springer; 2014. p. 131-40. (Book chapter)
2. Dispenzieri A, Lacy MQ, **Kumar S**. Multiple myeloma. In: Greer JP; et al editor. Wintrobe's clinical hematology. Thirteenth Edition. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2014. p. 2046-97. (Book chapter)
3. **Kumar S**, Russell SJ. Treatment of newly diagnosed multiple myeloma. In: Gertz MA; Rajkumar SV editor. Multiple myeloma: diagnosis and treatment. New York: Springer; 2014. p. 81-94. (Book chapter)
4. Mikhael J, **Kumar S**, Rajkumar SV. Approach to relapsed refractory myeloma. In: Gertz MA; Rajkumar SV editor. Multiple myeloma: diagnosed and treatment. New York: Springer; 2014. p. 95-100. (Book chapter)
5. Singla A, **Kumar S**. Newer IMiDs. In: Advances in biology and therapy of multiple myeloma. Volume 2. 2013. p. 181-213. (Book chapter)
6. **Kumar S**. Promising clinical trials in multiple myeloma. In: Multiple myeloma - a new era of treatment strategies. 2012. p. 120-7. (Book chapter)
7. **Kumar S**, Rajkumar SV. Multiple myeloma: molecular biology, diagnosis and treatment. In: Advances in malignant hematology. 2011. p. 315-41. (Book chapter)
8. Dispenzieri A, **Kumar S**. Current therapies for light-chain amyloidosis. In: Ramirez-Alvarado M; Kelly JW; Dobson CM editor. Protein misfolding diseases: current and emerging principles and therapies. Hoboken: Wiley; 2010. (Wiley Series in Protein and Peptide Science.). p. 775-93. (Book chapter)
9. **Kumar S**. Lenalidomide for initial therapy of newly diagnosed multiple myeloma. In: Lonial S, editor. Myeloma therapy: pursuing the plasma cell. Totowa: Humana; 2008. (Contemporary Hematology.). p. 279-88. (Book chapter)
10. Podar K, **Kumar S**, Chauhan D, Anderson KC. Pathophysiologic role of VEGF in hematologic malignancies. In: Davis DW, Herbst RS, Abbruzzese JL, editors. Antiangiogenic cancer therapy. Boca Raton: CRC Press; 2008. p. 91-129. (Book chapter)
11. **Kumar S**, Greipp PR. Monoclonal gammopathy of undetermined significance. In: Sekeres MA, Kalaycio ME, Bolwell BJ. Clinical malignant hematology. New York: McGraw-Hill Medical; 2007. p. 943-54. (Book chapter)

Editorials

1. **Kumar S**, Kyle RA. A new era in the management of multiple myeloma - The Ghobrial/Ghobrial/Mitsiades et al article reviewed. Oncology (Williston Park) 2007 Jun; 21(7):800.
2. **Kumar S**, Gertz MA. Cutaneous and systemic amyloidoses. Int J Dermatol. 2002 Mar; 41(3):133-4.

Commentaries

1. **Kumar S**. Blind men and an elephant. Blood. 2015 Jan 29; 125(5):745-7.

2. **Kumar SK**, Gertz MA. Risk adapted therapy for multiple myeloma: back to basics. *Leuk Lymphoma*. 2014 Oct; 55(10):2219-20. Epub 2014 Apr 22.
3. **Kumar SK**, Rajkumar SV. The current status of minimal residual disease assessment in myeloma. *Leukemia*. 2014 Feb; 28(2):239-40.
4. Dispenzieri A, **Kumar S**. Treatment for high-risk smoldering myeloma. *N Engl J Med*. 2013 Oct 31; 369(18):1764.
5. Palladini G, Dispenzieri A, Gertz M, **Kumar S**, Wechalekar A, Hawkins PN, Schonland S, Hegenbart U, Comenzo R, Kastritis E, Dimopoulos MA, Jaccard A, Klersy C, Merlini G. Reply to S. Girnius et al. *J Clin Oncol*. 2013 Jul 20; 31(21):2750-1.
6. Fonseca R, Richardson P, Giralt S, Lonial S, Rajkumar SV, Stewart AK, Bensinger W, Somlo G, Vescio R, Mikhael J, Reeder C, Tiedemann R, Tricot G, Rifkin R, Shaughnessy J, Munshi N, Raje N, Ghobrial I, Laubach J, Schlossman R, Treon S, Mahindra A, Avigan D, Rosenblatt J, Jagannath S, Niesvizky R, Landau H, Chen-Kiang S, Siegel DS, Zimmerman T, Mehta J, Vesole D, Rosen S, Hofmeister C, Lacy M, Dispenzieri A, Borrello I, Hayman SR, **Kumar S**, Buadi F, Dingli D, Russell S, Melissa Alsina MA, Fernandez H, Roy V, Pereira D, Stadtmauer E, Vij R, Jakubowiak A, Lentzsch S, Song K, Trudel S, Chen C, Reece D, Stewart D, Singhal S, Comenzo R, Gertz MA, Greipp PR, Durie B, Barlogie B, Anderson K, Dalton W, Coleman M, Novis S, Kyle RA. Conflicts of interest, authorship, and disclosures in industry-related scientific publications. *Mayo Clin Proc*. 2010 Feb; 85(2):197-9; author reply 201-4.
7. Madan S, **Kumar S**. Review: extramedullary disease in multiple myeloma. *Clin Adv Hematol Oncol*. 2009 Dec; 7(12):802-4.
8. Kyle RA, **Kumar S**. The significance of monoclonal gammopathy of undetermined significance. *Haematologica*. 2009 Dec; 94(12):1641-4.
9. **Kumar S**, Rajkumar SV. Commentary on myeloma presentations. *Clinical Advances in Hematology and Oncology*. 2009; 7(2 Suppl. 6):11-2.
10. **Kumar S**, Rajkumar SV. Many facets of bortezomib resistance/susceptibility. *Blood*. 2008 Sep 15; 112(6):2177-8.
11. **Kumar S**. Solitary plasmacytoma: is radiation therapy sufficient? *Am J Hematol*. 2008 Sep; 83(9):695-6.
12. **Kumar S**. Combination therapy with melphalan, prednisone, and thalidomide (MPT) for multiple myeloma. *American Journal of Hematology/Oncology*. 2006 Aug; 5(8):491-4.
13. **Kumar S**. Progress in the treatment of multiple myeloma. *Lancet*. 2006 Mar 11; 367(9513):791-2.

Letters

1. Rosenthal A, **Kumar S**, Hofmeister C, Laubach J, Vij R, Dueck A, Gano K, Stewart AK. A Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib (MLN8237) and Bortezomib in Relapsed Multiple Myeloma. *Br J Haematol*. 2015 Sep 25.
2. Costa LJ, Gonsalves WI, **Kumar SK**. Early mortality in multiple myeloma. *Leukemia*. 2015 Jul; 29(7):1616-8. Epub 2015 Feb 12.
3. Roy V, Stewart AK, Bergsagel PL, Dispenzieri A, Laumann K, Allred J, Lacy MQ, Fonseca R, Reeder CB, **Kumar S**, Rivera CE, Gertz MA, Buadi FK, Hayman SR, Rajkumar SV. Phase I/II study of melphalan, prednisone and lenalidomide combination

for patients with newly diagnosed multiple myeloma who are not candidates for stem cell transplantation. *Blood Cancer J.* 2015; 5:e294. Epub 2015 Mar 20.

4. Kourelis TV, **Kumar SK**, Srivastava G, Gertz MA, Lacy MQ, Buadi FK, Kyle RA, Dispenzieri A. Long-term response to lenalidomide in patients with newly diagnosed multiple myeloma. *Leukemia.* 2014 Feb; 28(2):455-7. Epub 2013 Oct 22.
5. Ding W, Shanafelt TD, Lesnick CE, Erlichman C, Leis JF, Secreto C, Sassoon TR, Call TG, Bowen DA, Conte M, **Kumar S**, Kay NE. Akt inhibitor MK2206 selectively targets CLL B-cell receptor induced cytokines, mobilizes lymphocytes and synergizes with bendamustine to induce CLL apoptosis. *Br J Haematol.* 2014 Jan; 164(1):146-50. Epub 2013 Sep 20.
6. Bang SM, Kyle RA, Rajkumar SV, **Kumar S**. Treatment patterns and outcomes in elderly patients with multiple myeloma. *Leukemia.* 2013 Apr; 27(4):971-4. Epub 2012 Sep 05.
7. Sinha S, Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK, Dingli D, Micallef IN, Hogan WJ, Gastineau DA, Rajkumar SV, **Kumar SK**. Majority of patients receiving initial therapy with lenalidomide-based regimens can be successfully mobilized with appropriate mobilization strategies. *Leukemia.* 2012 May; 26(5):1119-22. Epub 2011 Oct 28.
8. Sinha S, Lacy M, Mikhael J, Hayman S, Buadi F, Detweiler-Short K, Dispenzieri A, Gertz M, Dingli D, Rajkumar SV, **Kumar SK**. Response to salvage therapies and outcome in patients with multiple myeloma relapsing after pomalidomide therapy. *Leukemia.* 2012 Apr; 26(4):839-41. Epub 2011 Oct 11.
9. Kapoor P, **Kumar S**, Mandrekar SJ, Laumann KM, Dispenzieri A, Lacy MQ, Dingli D, Gertz MA, Kyle RA, Greipp PR, Rajkumar SV, Witzig TE. Efficacy of thalidomide- or lenalidomide-based therapy in proliferative multiple myeloma. *Leukemia.* 2011 Jul; 25(7):1195-7. Epub 2011 Apr 5.
10. Sadek I, Dispenzieri A, Gertz MA, **Kumar S**. Activity of bortezomib administered once every 3 weeks for treatment of relapsed multiple myeloma. *Leuk Lymphoma.* 2009 Jun; 50(6):1033-5.
11. Ng AC, **Kumar SK**, Russell SJ, Rajkumar SV, Drake MT. Dexamethasone and the risk for adrenal suppression in multiple myeloma. *Leukemia.* 2009 May; 23(5):1009-11. Epub 2009 Jan 08.
12. **Kumar S**, Gertz MA. Reply to 'Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients'. *Leukemia.* 2008 Jun; 22(6):1281-2.
13. **Kumar S**, Dispenzieri A, Gertz MA. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. *N Engl J Med.* 2008 Jan 3; 358(1):91; author reply 92-3.
14. **Kumar S**, Sarr MG, Kamath PS. Mesenteric venous thrombosis - Reply. *N Engl J Med.* 2002 Apr 18; 346(16):1253.
15. Riegert-Johnson DL, **Kumar S**, Volcheck GW. A patient with anaphylactoid hypersensitivity to intravenous cyclosporine and subcutaneous phytonadione (vitamin K(1)). *Bone Marrow Transplant.* 2001 Dec; 28(12):1176-7.